Trial Outcomes & Findings for Study to Evaluate the Pharmacokinetic (PK) Interactions Between GSK3640254 and Dolutegravir (DTG) (NCT NCT03816696)

Results Overview

Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis. Pharmacokinetic Parameter Population consisted of all participants who underwent plasma pharmacokinetic sampling and had evaluable pharmacokinetic parameters estimated.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

16 participants

Primary outcome timeframe

Day 5: Pre-dose, 1, 1.5, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

Results posted on

2020-03-19

Participant Flow

This was an open-label, fixed-sequence, two-way drug interaction and 3-period study. Participants received treatment A- dolutegravir 50 milligram (mg) in Period 1; treatment B- GSK3640254 200 mg in Period 2 and treatment C- dolutegravir 50 mg and GSK3640254 200 mg in Period 3.

A total of 30 participants were screened, of which 14 were screening failures. Hence, 16 participants were enrolled in this study. This study was conducted at a single center in the United States.

Participant milestones

Participant milestones
Measure	Dolutegravir/GSK3640254/Dolutegravir+GSK3640254 Participants received treatment A- dolutegravir 50 mg, tablets, orally, once daily on Days 1 to 5 in Period 1; followed by washout period of 4 days between last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2; followed by treatment B- GSK3640254 200 mg, capsules, orally, once daily on Days 1 to 7 in Period 2; further followed by treatment C- dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally, once daily on Days 1 to 7 in Period 3.
Period 1 (Up to Day 5) STARTED	16
Period 1 (Up to Day 5) COMPLETED	16
Period 1 (Up to Day 5) NOT COMPLETED	0
Wash Out Period (Days 6 to 9) STARTED	16
Wash Out Period (Days 6 to 9) COMPLETED	16
Wash Out Period (Days 6 to 9) NOT COMPLETED	0
Period 2 (Up to Day 7) STARTED	16
Period 2 (Up to Day 7) COMPLETED	16
Period 2 (Up to Day 7) NOT COMPLETED	0
Period 3 (Up to Day 11) STARTED	16
Period 3 (Up to Day 11) COMPLETED	16
Period 3 (Up to Day 11) NOT COMPLETED	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Study to Evaluate the Pharmacokinetic (PK) Interactions Between GSK3640254 and Dolutegravir (DTG)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Dolutegravir/GSK3640254/Dolutegravir+GSK3640254 n=16 Participants Participants received treatment A- dolutegravir 50 mg, tablets, orally, once daily on Days 1 to 5 in Period 1; followed by washout period of 4 days between last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2; followed by treatment B- GSK3640254 200 mg, capsules, orally, once daily on Days 1 to 7 in Period 2; further followed by treatment C- dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally, once daily on Days 1 to 7 in Period 3.
Age, Continuous	36.7 Years STANDARD_DEVIATION 10.66 • n=5 Participants
Sex: Female, Male Female	1 Participants n=5 Participants
Sex: Female, Male Male	15 Participants n=5 Participants
Race/Ethnicity, Customized Asian - East Asian Heritage	1 Participants n=5 Participants
Race/Ethnicity, Customized Asian - South East Asian Heritage	1 Participants n=5 Participants
Race/Ethnicity, Customized Black or African American	3 Participants n=5 Participants
Race/Ethnicity, Customized White - White/Caucasian/European Heritage	11 Participants n=5 Participants

PRIMARY outcome

Timeframe: Day 5: Pre-dose, 1, 1.5, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

Population: Pharmacokinetic Parameter Population.

Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis. Pharmacokinetic Parameter Population consisted of all participants who underwent plasma pharmacokinetic sampling and had evaluable pharmacokinetic parameters estimated.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Area Under the Plasma Concentration-time Curve From Time 0 to the End of the Dosing (AUC[0 to Tau]) of Dolutegravir for Dolutegravir Arm	64627.8 Hours* nanogram per milliliter Geometric Coefficient of Variation 20.1	—	—

PRIMARY outcome

Timeframe: Day 7: Pre-dose, 1, 1.5, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

Population: Pharmacokinetic Parameter Population.

Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: AUC(0 to Tau) of Dolutegravir for Dolutegravir + GSK3640254 Arm	75860.5 Hours* nanogram per milliliter Geometric Coefficient of Variation 22.7	—	—

PRIMARY outcome

Timeframe: Day 5: Pre-dose, 1, 1.5, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

Population: Pharmacokinetic Parameter Population.

Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Maximum Observed Concentration (Cmax) of Dolutegravir for Dolutegravir Arm	4962 Nanogram per milliliter Geometric Coefficient of Variation 16.5	—	—

PRIMARY outcome

Timeframe: Day 7: Pre-dose, 1, 1.5, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

Population: Pharmacokinetic Parameter Population.

Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Cmax of Dolutegravir for Dolutegravir + GSK3640254 Arm	5408 Nanogram per milliliter Geometric Coefficient of Variation 17.2	—	—

PRIMARY outcome

Timeframe: Day 5: Pre-dose, 1, 1.5, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

Population: Pharmacokinetic Parameter Population.

Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Plasma Concentration at the End of the Dosing Interval (Ctau) of Dolutegravir for Dolutegravir Arm	1373 Nanogram per milliliter Geometric Coefficient of Variation 30.6	—	—

PRIMARY outcome

Timeframe: Day 7: Pre-dose, 1, 1.5, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

Population: Pharmacokinetic Parameter Population.

Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Ctau of Dolutegravir for Dolutegravir + GSK3640254 Arm	1696 Nanogram per milliliter Geometric Coefficient of Variation 31.1	—	—

PRIMARY outcome

Timeframe: Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

Population: Pharmacokinetic Parameter Population.

Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: AUC(0 to Tau) of GSK3640254 for GSK3640254 Arm	26.72 Hours* microgram per milliliter Geometric Coefficient of Variation 32.3	—	—

PRIMARY outcome

Timeframe: Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

Population: Pharmacokinetic Parameter Population.

Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: AUC(0 to Tau) of GSK3640254 for Dolutegravir + GSK3640254 Arm	27.84 Hours* microgram per milliliter Geometric Coefficient of Variation 30.1	—	—

PRIMARY outcome

Timeframe: Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

Population: Pharmacokinetic Parameter Population.

Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Cmax of GSK3640254 for GSK3640254 Arm	1.676 Microgram per milliliter Geometric Coefficient of Variation 26.4	—	—

PRIMARY outcome

Timeframe: Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

Population: Pharmacokinetic Parameter Population.

Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Cmax of GSK3640254 for Dolutegravir + GSK3640254 Arm	1.662 Microgram per milliliter Geometric Coefficient of Variation 26.8	—	—

PRIMARY outcome

Timeframe: Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

Population: Pharmacokinetic Parameter Population.

Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Ctau of GSK3640254 for GSK3640254 Arm	0.8583 Microgram per milliliter Geometric Coefficient of Variation 38.3	—	—

PRIMARY outcome

Timeframe: Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

Population: Pharmacokinetic Parameter Population.

Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Ctau of GSK3640254 for Dolutegravir + GSK3640254 Arm	0.8549 Microgram per milliliter Geometric Coefficient of Variation 34.1	—	—

SECONDARY outcome

Timeframe: Up to Day 27

Population: Safety Population.

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; and other important medical events which may require medical or surgical intervention. Safety Population consisted of all participants who received at least 1 dose of study medication.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg n=16 Participants In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg n=16 Participants In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs) Non-SAEs	1 Participants	3 Participants	2 Participants
Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs) SAEs	0 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: Baseline (Day -1) and at Day 9

Population: Safety Population.

Blood samples were collected to analyze the hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelet count. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Basophils	-0.003 10^9 cells per liter Standard Deviation 0.0124	—	—
Period 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Eosinophils	0.046 10^9 cells per liter Standard Deviation 0.1198	—	—
Period 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Lymphocytes	0.013 10^9 cells per liter Standard Deviation 0.3793	—	—
Period 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Monocytes	-0.020 10^9 cells per liter Standard Deviation 0.0829	—	—
Period 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Neutrophils	-0.217 10^9 cells per liter Standard Deviation 0.6421	—	—
Period 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Platelet count	-6.5 10^9 cells per liter Standard Deviation 21.73	—	—

SECONDARY outcome

Timeframe: Baseline (Period 1 Day 9) and at Day 7

Population: Safety Population.

Blood samples were collected to analyze the hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelet count. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Lymphocytes	-0.154 10^9 cells per liter Standard Deviation 0.2718	—	—
Period 2: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Monocytes	-0.024 10^9 cells per liter Standard Deviation 0.0701	—	—
Period 2: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Neutrophils	-0.160 10^9 cells per liter Standard Deviation 0.3762	—	—
Period 2: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Platelet count	-6.0 10^9 cells per liter Standard Deviation 30.58	—	—
Period 2: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Basophils	-0.006 10^9 cells per liter Standard Deviation 0.0089	—	—
Period 2: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Eosinophils	-0.026 10^9 cells per liter Standard Deviation 0.0810	—	—

SECONDARY outcome

Timeframe: Baseline (Period 2 Day 7) and at Days 4, 7 and 10

Population: Safety Population. Only those participants with data available at the indicated time points were analyzed (represented by n= X in the category titles).

Blood samples were collected to analyze the hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelet count. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Day 7: Basophils, n=16	0.007 10^9 cells per liter Standard Deviation 0.0135	—	—
Period 3: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Day 4: Eosinophils, n=16	-0.001 10^9 cells per liter Standard Deviation 0.0448	—	—
Period 3: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Day 10: Lymphocytes, n=16	-0.117 10^9 cells per liter Standard Deviation 0.2628	—	—
Period 3: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Day 4: Monocytes, n=16	0.049 10^9 cells per liter Standard Deviation 0.1627	—	—
Period 3: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Day 10: Monocytes, n=16	-0.018 10^9 cells per liter Standard Deviation 0.0693	—	—
Period 3: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Day 7: Neutrophils, n=16	0.076 10^9 cells per liter Standard Deviation 0.5969	—	—
Period 3: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Day 10: Neutrophils, n=16	0.204 10^9 cells per liter Standard Deviation 0.5116	—	—
Period 3: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Day 4: Basophils, n=16	0.003 10^9 cells per liter Standard Deviation 0.0101	—	—
Period 3: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Day 10: Basophils, n=16	0.003 10^9 cells per liter Standard Deviation 0.0144	—	—
Period 3: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Day 7: Eosinophils, n=16	0.004 10^9 cells per liter Standard Deviation 0.0846	—	—
Period 3: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Day 10: Eosinophils, n=16	-0.036 10^9 cells per liter Standard Deviation 0.0468	—	—
Period 3: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Day 4: Lymphocytes, n=16	-0.130 10^9 cells per liter Standard Deviation 0.2931	—	—
Period 3: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Day 7: Lymphocytes, n=16	-0.033 10^9 cells per liter Standard Deviation 0.3260	—	—
Period 3: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Day 7: Monocytes, n=16	0.003 10^9 cells per liter Standard Deviation 0.0850	—	—
Period 3: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Day 4: Neutrophils, n=16	0.443 10^9 cells per liter Standard Deviation 1.5098	—	—
Period 3: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Day 4: Platelet count, n=16	-4.9 10^9 cells per liter Standard Deviation 11.08	—	—
Period 3: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Day 7: Platelet count, n=15	-11.5 10^9 cells per liter Standard Deviation 12.03	—	—
Period 3: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Day 10: Platelet count, n=16	-5.9 10^9 cells per liter Standard Deviation 16.50	—	—

SECONDARY outcome

Timeframe: Baseline (Day -1) and at Day 9

Population: Safety Population.

Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Change From Baseline in Hematology Parameter: Hemoglobin	4.4 Grams per liter Standard Deviation 5.97	—	—

SECONDARY outcome

Timeframe: Baseline (Period 1 Day 9) and at Day 7

Population: Safety Population.

Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Change From Baseline in Hematology Parameter: Hemoglobin	0.1 Grams per liter Standard Deviation 2.53	—	—

SECONDARY outcome

Timeframe: Baseline (Period 2 Day 7) and at Days 4, 7 and 10

Population: Safety Population.

Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Change From Baseline in Hematology Parameter: Hemoglobin Day 4	3.3 Grams per liter Standard Deviation 3.00	—	—
Period 3: Change From Baseline in Hematology Parameter: Hemoglobin Day 7	0.6 Grams per liter Standard Deviation 3.50	—	—
Period 3: Change From Baseline in Hematology Parameter: Hemoglobin Day 10	1.2 Grams per liter Standard Deviation 3.69	—	—

SECONDARY outcome

Timeframe: Baseline (Day -1) and at Day 9

Population: Safety Population.

Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Change From Baseline in Hematology Parameter: Hematocrit	0.0178 Proportion of red blood cells in blood Standard Deviation 0.01988	—	—

SECONDARY outcome

Timeframe: Baseline (Period 1 Day 9) and at Day 7

Population: Safety Population.

Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Change From Baseline in Hematology Parameter: Hematocrit	-0.0013 Proportion of red blood cells in blood Standard Deviation 0.00948	—	—

SECONDARY outcome

Timeframe: Baseline (Period 2 Day 7) and at Days 4, 7 and 10

Population: Safety Population.

Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Change From Baseline in Hematology Parameter: Hematocrit Day 4	0.0035 Proportion of red blood cells in blood Standard Deviation 0.00794	—	—
Period 3: Change From Baseline in Hematology Parameter: Hematocrit Day 10	-0.0041 Proportion of red blood cells in blood Standard Deviation 0.01402	—	—
Period 3: Change From Baseline in Hematology Parameter: Hematocrit Day 7	-0.0049 Proportion of red blood cells in blood Standard Deviation 0.01101	—	—

SECONDARY outcome

Timeframe: Baseline (Day -1) and at Day 9

Population: Safety Population.

Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Change From Baseline in Hematology Parameter: Erythrocytes	0.170 Trillion cells per liter Standard Deviation 0.2080	—	—

SECONDARY outcome

Timeframe: Baseline (Period 1 Day 9) and at Day 7

Population: Safety Population.

Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Change From Baseline in Hematology Parameter: Erythrocytes	0.036 Trillion cells per liter Standard Deviation 0.1020	—	—

SECONDARY outcome

Timeframe: Baseline (Period 2 Day 7) and at Days 4, 7 and 10

Population: Safety Population.

Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Change From Baseline in Hematology Parameter: Erythrocytes Day 7	-0.079 Trillion cells per liter Standard Deviation 0.1038	—	—
Period 3: Change From Baseline in Hematology Parameter: Erythrocytes Day 10	-0.054 Trillion cells per liter Standard Deviation 0.1540	—	—
Period 3: Change From Baseline in Hematology Parameter: Erythrocytes Day 4	0.016 Trillion cells per liter Standard Deviation 0.0943	—	—

SECONDARY outcome

Timeframe: Baseline (Day -1) and at Day 9

Population: Safety Population.

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume	0.63 Femtoliter Standard Deviation 0.774	—	—

SECONDARY outcome

Timeframe: Baseline (Period 1 Day 9) and at Day 7

Population: Safety Population.

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume	-0.86 Femtoliter Standard Deviation 0.564	—	—

SECONDARY outcome

Timeframe: Baseline (Period 2 Day 7) and at Days 4, 7 and 10

Population: Safety Population.

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume Day 7	0.36 Femtoliter Standard Deviation 0.762	—	—
Period 3: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume Day 10	0.05 Femtoliter Standard Deviation 0.954	—	—
Period 3: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume Day 4	0.40 Femtoliter Standard Deviation 0.542	—	—

SECONDARY outcome

Timeframe: Baseline (Day -1) and at Day 9

Population: Safety Population.

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin	-0.11 Picograms Standard Deviation 0.279	—	—

SECONDARY outcome

Timeframe: Baseline (Period 1 Day 9) and at Day 7

Population: Safety Population.

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin	-0.17 Picograms Standard Deviation 0.218	—	—

SECONDARY outcome

Timeframe: Baseline (Period 2 Day 7) and at Days 4, 7 and 10

Population: Safety Population.

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin Day 4	0.55 Picograms Standard Deviation 0.225	—	—
Period 3: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin Day 7	0.55 Picograms Standard Deviation 0.329	—	—
Period 3: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin Day 10	0.52 Picograms Standard Deviation 0.315	—	—

SECONDARY outcome

Timeframe: Baseline (Day -1) and at Day 9

Population: Safety Population.

Blood samples were collected to analyze the chemistry parameters: glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and blood urea nitrogen. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Glucose	0.063 Millimoles per liter Standard Deviation 0.4235	—	—
Period 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Anion gap	-1.2 Millimoles per liter Standard Deviation 1.33	—	—
Period 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Calcium	0.025 Millimoles per liter Standard Deviation 0.0599	—	—
Period 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Potassium	0.05 Millimoles per liter Standard Deviation 0.356	—	—
Period 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Sodium	0.3 Millimoles per liter Standard Deviation 2.15	—	—
Period 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Blood urea nitrogen	0.297 Millimoles per liter Standard Deviation 0.9823	—	—
Period 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Cholesterol	0.088 Millimoles per liter Standard Deviation 0.6858	—	—
Period 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Triglycerides	-0.084 Millimoles per liter Standard Deviation 0.3983	—	—
Period 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Carbon dioxide	-0.1 Millimoles per liter Standard Deviation 2.03	—	—
Period 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Chloride	1.6 Millimoles per liter Standard Deviation 2.63	—	—
Period 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Phosphate	0.091 Millimoles per liter Standard Deviation 0.1531	—	—

SECONDARY outcome

Timeframe: Baseline (Period 1 Day 9) and at Day 7

Population: Safety Population.

Blood samples were collected to analyze the chemistry parameters: glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and blood urea nitrogen. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Glucose	-0.249 Millimoles per liter Standard Deviation 0.1748	—	—
Period 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Cholesterol	-0.269 Millimoles per liter Standard Deviation 0.2363	—	—
Period 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Triglycerides	0.087 Millimoles per liter Standard Deviation 0.2374	—	—
Period 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Anion gap	2.2 Millimoles per liter Standard Deviation 1.52	—	—
Period 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Calcium	0.014 Millimoles per liter Standard Deviation 0.0245	—	—
Period 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Carbon dioxide	-1.3 Millimoles per liter Standard Deviation 1.53	—	—
Period 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Chloride	-0.7 Millimoles per liter Standard Deviation 1.78	—	—
Period 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Phosphate	0.037 Millimoles per liter Standard Deviation 0.0955	—	—
Period 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Potassium	-0.03 Millimoles per liter Standard Deviation 0.272	—	—
Period 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Sodium	0.3 Millimoles per liter Standard Deviation 1.74	—	—
Period 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Blood urea nitrogen	-0.341 Millimoles per liter Standard Deviation 0.3937	—	—

SECONDARY outcome

Timeframe: Baseline (Period 2 Day 7) and at Days 4, 7 and 10

Population: Safety Population.

Blood samples were collected to analyze the chemistry parameters: glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and blood urea nitrogen. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 10: Glucose	-0.066 Millimoles per liter Standard Deviation 0.2205	—	—
Period 3: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 4: Triglycerides	0.034 Millimoles per liter Standard Deviation 0.2316	—	—
Period 3: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 7: Triglycerides	-0.094 Millimoles per liter Standard Deviation 0.2578	—	—
Period 3: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 7: Anion gap	0.1 Millimoles per liter Standard Deviation 1.69	—	—
Period 3: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 7: Chloride	-0.3 Millimoles per liter Standard Deviation 1.39	—	—
Period 3: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 4: Glucose	0.062 Millimoles per liter Standard Deviation 0.1638	—	—
Period 3: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 7: Glucose	0.103 Millimoles per liter Standard Deviation 0.1806	—	—
Period 3: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 4: Cholesterol	0.096 Millimoles per liter Standard Deviation 0.2400	—	—
Period 3: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 7: Cholesterol	-0.008 Millimoles per liter Standard Deviation 0.2693	—	—
Period 3: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 10: Cholesterol	-0.030 Millimoles per liter Standard Deviation 0.2366	—	—
Period 3: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 10: Triglycerides	0.095 Millimoles per liter Standard Deviation 0.2178	—	—
Period 3: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 4: Anion gap	-4.1 Millimoles per liter Standard Deviation 1.24	—	—
Period 3: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 10: Anion gap	0.8 Millimoles per liter Standard Deviation 1.65	—	—
Period 3: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 4: Calcium	-0.003 Millimoles per liter Standard Deviation 0.0416	—	—
Period 3: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 7: Calcium	0.026 Millimoles per liter Standard Deviation 0.0413	—	—
Period 3: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 10: Calcium:	0.035 Millimoles per liter Standard Deviation 0.0561	—	—
Period 3: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 4: Carbon dioxide	0.9 Millimoles per liter Standard Deviation 1.65	—	—
Period 3: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 7: Carbon dioxide	0.1 Millimoles per liter Standard Deviation 1.59	—	—
Period 3: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 10: Carbon dioxide	1.0 Millimoles per liter Standard Deviation 2.16	—	—
Period 3: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 4: Chloride	0.7 Millimoles per liter Standard Deviation 1.92	—	—
Period 3: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 10: Chloride	-1.1 Millimoles per liter Standard Deviation 1.86	—	—
Period 3: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 4: Phosphate	-0.004 Millimoles per liter Standard Deviation 0.0808	—	—
Period 3: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 7: Phosphate	-0.013 Millimoles per liter Standard Deviation 0.1151	—	—
Period 3: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 10: Phosphate	-0.051 Millimoles per liter Standard Deviation 0.1115	—	—
Period 3: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 4: Potassium	-0.04 Millimoles per liter Standard Deviation 0.239	—	—
Period 3: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 7: Potassium	-0.03 Millimoles per liter Standard Deviation 0.218	—	—
Period 3: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 10: Potassium	0.06 Millimoles per liter Standard Deviation 0.189	—	—
Period 3: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 4: Sodium	-2.0 Millimoles per liter Standard Deviation 1.37	—	—
Period 3: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 7: Sodium	-0.1 Millimoles per liter Standard Deviation 1.65	—	—
Period 3: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 10: Sodium	0.5 Millimoles per liter Standard Deviation 1.90	—	—
Period 3: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 4: Blood urea nitrogen	0.054 Millimoles per liter Standard Deviation 0.5287	—	—
Period 3: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 7: Blood urea nitrogen	-0.178 Millimoles per liter Standard Deviation 0.3542	—	—
Period 3: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 10: Blood urea nitrogen	-0.026 Millimoles per liter Standard Deviation 0.5156	—	—

SECONDARY outcome

Timeframe: Baseline (Day -1) and at Day 9

Population: Safety Population.

Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase Creatine kinase	-32.0 International units per liter Standard Deviation 61.33	—	—
Period 1: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase Lactate dehydrogenase	-21.9 International units per liter Standard Deviation 14.16	—	—
Period 1: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase ALT	-0.3 International units per liter Standard Deviation 8.28	—	—
Period 1: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase ALP	-0.1 International units per liter Standard Deviation 7.67	—	—
Period 1: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase AST	-0.7 International units per liter Standard Deviation 3.36	—	—
Period 1: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase Gamma-glutamyl transferase	-2.1 International units per liter Standard Deviation 3.13	—	—

SECONDARY outcome

Timeframe: Baseline (Period 1 Day 9) and at Day 7

Population: Safety Population.

Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Creatine kinase	22.6 International units per liter Standard Deviation 58.21	—	—
Period 2: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Lactate dehydrogenase	9.1 International units per liter Standard Deviation 5.76	—	—
Period 2: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase ALT	-0.6 International units per liter Standard Deviation 2.80	—	—
Period 2: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase ALP	1.9 International units per liter Standard Deviation 2.70	—	—
Period 2: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase AST	0.2 International units per liter Standard Deviation 1.87	—	—
Period 2: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Gamma-glutamyl transferase	-0.8 International units per liter Standard Deviation 1.28	—	—

SECONDARY outcome

Timeframe: Baseline (Period 2 Day 7) and at Days 4, 7 and 10

Population: Safety Population.

Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Day 10: Gamma-glutamyl transferase	0.5 International units per liter Standard Deviation 1.51	—	—
Period 3: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Day 4: Creatine kinase	-32.1 International units per liter Standard Deviation 131.30	—	—
Period 3: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Day 7: Creatine kinase	-37.1 International units per liter Standard Deviation 158.35	—	—
Period 3: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Day 10: Creatine kinase	-42.1 International units per liter Standard Deviation 162.94	—	—
Period 3: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Day 4: Lactate dehydrogenase	5.9 International units per liter Standard Deviation 7.38	—	—
Period 3: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Day 7: Lactate dehydrogenase	-0.9 International units per liter Standard Deviation 7.02	—	—
Period 3: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Day 10: Lactate dehydrogenase	0.1 International units per liter Standard Deviation 10.32	—	—
Period 3: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Day 4: ALT	1.1 International units per liter Standard Deviation 4.36	—	—
Period 3: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Day 7: ALT	0.7 International units per liter Standard Deviation 4.69	—	—
Period 3: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Day 10: ALT	1.9 International units per liter Standard Deviation 4.11	—	—
Period 3: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Day 4: ALP	-1.6 International units per liter Standard Deviation 2.00	—	—
Period 3: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Day 7: ALP	-0.6 International units per liter Standard Deviation 2.39	—	—
Period 3: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Day 10: ALP	0.8 International units per liter Standard Deviation 4.06	—	—
Period 3: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Day 4: AST	0.9 International units per liter Standard Deviation 2.45	—	—
Period 3: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Day 7: AST	-0.5 International units per liter Standard Deviation 2.68	—	—
Period 3: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Day 10: AST	0.3 International units per liter Standard Deviation 2.29	—	—
Period 3: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Day 4: Gamma-glutamyl transferase	-0.8 International units per liter Standard Deviation 0.75	—	—
Period 3: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Day 7: Gamma-glutamyl transferase	-0.3 International units per liter Standard Deviation 1.06	—	—

SECONDARY outcome

Timeframe: Baseline (Day -1) and at Day 9

Population: Safety Population.

Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Change From Baseline in Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Creatinine	5.41 Micromoles per liter Standard Deviation 7.253	—	—
Period 1: Change From Baseline in Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Bilirubin	0.01 Micromoles per liter Standard Deviation 4.516	—	—
Period 1: Change From Baseline in Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Urate	-32.3 Micromoles per liter Standard Deviation 42.01	—	—
Period 1: Change From Baseline in Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Direct bilirubin	0.03 Micromoles per liter Standard Deviation 0.677	—	—

SECONDARY outcome

Timeframe: Baseline (Period 1 Day 9) and at Day 7

Population: Safety Population.

Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Change From Baseline in Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Urate	-7.1 Micromoles per liter Standard Deviation 14.52	—	—
Period 2: Change From Baseline in Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Creatinine	-3.36 Micromoles per liter Standard Deviation 4.219	—	—
Period 2: Change From Baseline in Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Bilirubin	0.27 Micromoles per liter Standard Deviation 1.299	—	—
Period 2: Change From Baseline in Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Direct bilirubin	0.06 Micromoles per liter Standard Deviation 0.328	—	—

SECONDARY outcome

Timeframe: Baseline (Period 2 Day 7) and at Days 4, 7 and 10

Population: Safety Population.

Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Change From Baseline in Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Day 7: Direct bilirubin	-0.19 Micromoles per liter Standard Deviation 0.436	—	—
Period 3: Change From Baseline in Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Day 4: Urate	0.0 Micromoles per liter Standard Deviation 16.23	—	—
Period 3: Change From Baseline in Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Day 7: Urate	-15.6 Micromoles per liter Standard Deviation 26.39	—	—
Period 3: Change From Baseline in Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Day 10: Urate	-1.4 Micromoles per liter Standard Deviation 24.69	—	—
Period 3: Change From Baseline in Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Day 4: Creatinine	7.90 Micromoles per liter Standard Deviation 4.239	—	—
Period 3: Change From Baseline in Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Day 7: Creatinine	9.89 Micromoles per liter Standard Deviation 4.014	—	—
Period 3: Change From Baseline in Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Day 10: Creatinine	1.99 Micromoles per liter Standard Deviation 4.739	—	—
Period 3: Change From Baseline in Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Day 4: Bilirubin	2.24 Micromoles per liter Standard Deviation 2.659	—	—
Period 3: Change From Baseline in Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Day 7: Bilirubin	-0.21 Micromoles per liter Standard Deviation 1.455	—	—
Period 3: Change From Baseline in Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Day 10: Bilirubin	1.43 Micromoles per liter Standard Deviation 2.011	—	—
Period 3: Change From Baseline in Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Day 4: Direct bilirubin	0.33 Micromoles per liter Standard Deviation 0.425	—	—
Period 3: Change From Baseline in Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Day 10: Direct bilirubin	0.22 Micromoles per liter Standard Deviation 0.248	—	—

SECONDARY outcome

Timeframe: Baseline (Day -1) and at Day 9

Population: Safety Population.

Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Change From Baseline in Chemistry Parameters: Albumin, Globulin, Protein Albumin	0.4 Grams per liter Standard Deviation 2.45	—	—
Period 1: Change From Baseline in Chemistry Parameters: Albumin, Globulin, Protein Globulin	0.8 Grams per liter Standard Deviation 1.11	—	—
Period 1: Change From Baseline in Chemistry Parameters: Albumin, Globulin, Protein Protein	1.2 Grams per liter Standard Deviation 3.06	—	—

SECONDARY outcome

Timeframe: Baseline (Period 1 Day 9) and at Day 7

Population: Safety Population.

Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Change From Baseline in Chemistry Parameters: Albumin, Globulin, Protein Albumin	0.9 Grams per liter Standard Deviation 1.45	—	—
Period 2: Change From Baseline in Chemistry Parameters: Albumin, Globulin, Protein Globulin	-1.1 Grams per liter Standard Deviation 0.77	—	—
Period 2: Change From Baseline in Chemistry Parameters: Albumin, Globulin, Protein Protein	-0.2 Grams per liter Standard Deviation 1.76	—	—

SECONDARY outcome

Timeframe: Baseline (Period 2 Day 7) and at Days 4, 7 and 10

Population: Safety Population.

Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Change From Baseline in Chemistry Parameters: Albumin, Globulin, Protein Day 10: Albumin	0.4 Grams per liter Standard Deviation 2.06	—	—
Period 3: Change From Baseline in Chemistry Parameters: Albumin, Globulin, Protein Day 4: Globulin	-0.9 Grams per liter Standard Deviation 1.29	—	—
Period 3: Change From Baseline in Chemistry Parameters: Albumin, Globulin, Protein Day 4: Albumin	0.9 Grams per liter Standard Deviation 1.00	—	—
Period 3: Change From Baseline in Chemistry Parameters: Albumin, Globulin, Protein Day 7: Albumin	0.2 Grams per liter Standard Deviation 1.22	—	—
Period 3: Change From Baseline in Chemistry Parameters: Albumin, Globulin, Protein Day 7: Globulin	1.0 Grams per liter Standard Deviation 1.10	—	—
Period 3: Change From Baseline in Chemistry Parameters: Albumin, Globulin, Protein Day 10: Globulin	0.5 Grams per liter Standard Deviation 1.32	—	—
Period 3: Change From Baseline in Chemistry Parameters: Albumin, Globulin, Protein Day 4: Protein	0.0 Grams per liter Standard Deviation 1.75	—	—
Period 3: Change From Baseline in Chemistry Parameters: Albumin, Globulin, Protein Day 7: Protein	1.2 Grams per liter Standard Deviation 1.80	—	—
Period 3: Change From Baseline in Chemistry Parameters: Albumin, Globulin, Protein Day 10: Protein	0.9 Grams per liter Standard Deviation 2.90	—	—

SECONDARY outcome

Timeframe: Baseline (Day -1) and at Day 9

Population: Safety Population.

Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Change From Baseline in Chemistry Parameters: Amylase, Lipase Amylase	3.1 Units per liter Standard Deviation 9.63	—	—
Period 1: Change From Baseline in Chemistry Parameters: Amylase, Lipase Lipase	-3.4 Units per liter Standard Deviation 8.97	—	—

SECONDARY outcome

Timeframe: Baseline (Period 1 Day 9) and at Day 7

Population: Safety Population.

Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Change From Baseline in Chemistry Parameters: Amylase, Lipase Amylase	-2.8 Units per liter Standard Deviation 4.65	—	—
Period 2: Change From Baseline in Chemistry Parameters: Amylase, Lipase Lipase	-0.7 Units per liter Standard Deviation 3.79	—	—

SECONDARY outcome

Timeframe: Baseline (Period 2 Day 7) and at Days 4, 7 and 10

Population: Safety Population.

Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Change From Baseline in Chemistry Parameters: Amylase, Lipase Day 4: Amylase	-1.6 Units per liter Standard Deviation 3.18	—	—
Period 3: Change From Baseline in Chemistry Parameters: Amylase, Lipase Day 7: Amylase	0.1 Units per liter Standard Deviation 4.25	—	—
Period 3: Change From Baseline in Chemistry Parameters: Amylase, Lipase Day 10: Amylase	-0.9 Units per liter Standard Deviation 6.08	—	—
Period 3: Change From Baseline in Chemistry Parameters: Amylase, Lipase Day 4: Lipase	4.7 Units per liter Standard Deviation 6.10	—	—
Period 3: Change From Baseline in Chemistry Parameters: Amylase, Lipase Day 7: Lipase	-0.8 Units per liter Standard Deviation 4.76	—	—
Period 3: Change From Baseline in Chemistry Parameters: Amylase, Lipase Day 10: Lipase	0.1 Units per liter Standard Deviation 5.24	—	—

SECONDARY outcome

Timeframe: Baseline (Day -1) and at Day 9

Population: Safety Population.

Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Change From Baseline in Urinalysis Parameter: Specific Gravity	0.0053 Ratio Standard Deviation 0.00865	—	—

SECONDARY outcome

Timeframe: Baseline (Period 1 Day 9) and at Day 7

Population: Safety Population.

Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Change From Baseline in Urinalysis Parameter: Specific Gravity	-0.0004 Ratio Standard Deviation 0.00645	—	—

SECONDARY outcome

Timeframe: Baseline (Period 2 Day 7) and at Days 4, 7 and 10

Population: Safety Population.

Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Change From Baseline in Urinalysis Parameter: Specific Gravity Day 4	0.0003 Ratio Standard Deviation 0.00652	—	—
Period 3: Change From Baseline in Urinalysis Parameter: Specific Gravity Day 7	-0.0007 Ratio Standard Deviation 0.00545	—	—
Period 3: Change From Baseline in Urinalysis Parameter: Specific Gravity Day 10	-0.0016 Ratio Standard Deviation 0.00901	—	—

SECONDARY outcome

Timeframe: Baseline (Day -1) and at Day 9

Population: Safety Population.

Urine samples were collected to analyze the urinalysis parameter: urobilinogen. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Change From Baseline in Urinalysis Parameter: Urobilinogen	0.0000 Micromoles per liter Standard Deviation 0.00000	—	—

SECONDARY outcome

Timeframe: Baseline (Period 1 Day 9) and at Day 7

Population: Safety Population.

Urine samples were collected to analyze the urinalysis parameter: urobilinogen. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Change From Baseline in Urinalysis Parameter: Urobilinogen	0.0000 Micromoles per liter Standard Deviation 0.00000	—	—

SECONDARY outcome

Timeframe: Baseline (Period 2 Day 7) and at Days 4, 7 and 10

Population: Safety Population.

Urine samples were collected to analyze the urinalysis parameter: urobilinogen. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Change From Baseline in Urinalysis Parameter: Urobilinogen Day 4	0.0000 Micromoles per liter Standard Deviation 0.00000	—	—
Period 3: Change From Baseline in Urinalysis Parameter: Urobilinogen Day 7	0.0000 Micromoles per liter Standard Deviation 0.00000	—	—
Period 3: Change From Baseline in Urinalysis Parameter: Urobilinogen Day 10	0.0000 Micromoles per liter Standard Deviation 0.00000	—	—

SECONDARY outcome

Timeframe: Baseline (Day -1) and at Day 9

Population: Safety Population.

Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Change From Baseline in Urinalysis Parameter: Potential of Hydrogen (pH)	-0.22 pH Standard Deviation 0.730	—	—

SECONDARY outcome

Timeframe: Baseline (Period 1 Day 9) and at Day 7

Population: Safety Population.

Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Change From Baseline in Urinalysis Parameter: pH	0.13 pH Standard Deviation 0.428	—	—

SECONDARY outcome

Timeframe: Baseline (Period 2 Day 7) and at Days 4, 7 and 10

Population: Safety Population.

Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Change From Baseline in Urinalysis Parameter: pH Day 4	0.03 pH Standard Deviation 0.531	—	—
Period 3: Change From Baseline in Urinalysis Parameter: pH Day 7	-0.13 pH Standard Deviation 0.500	—	—
Period 3: Change From Baseline in Urinalysis Parameter: pH Day 10	0.16 pH Standard Deviation 0.569	—	—

SECONDARY outcome

Timeframe: Day 9

Population: Safety Population.

Urine samples were collected at indicated time points to analyze parameters including glucose, protein, occult blood, ketones, nitrite, bilirubin and leukocyte esterase levels by dipstick. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters can be read as negative, Trace, 1+ (low concentrations present) and 2+ (moderate concentrations present) indicating proportional concentrations in the urine sample.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Number of Participants With Urinalysis Dipstick Results Ketones: Negative	15 Participants	—	—
Period 1: Number of Participants With Urinalysis Dipstick Results Bilirubin: Negative	16 Participants	—	—
Period 1: Number of Participants With Urinalysis Dipstick Results Glucose: Negative	16 Participants	—	—
Period 1: Number of Participants With Urinalysis Dipstick Results Ketones: Trace	1 Participants	—	—
Period 1: Number of Participants With Urinalysis Dipstick Results Leukocyte Esterase: Negative	16 Participants	—	—
Period 1: Number of Participants With Urinalysis Dipstick Results Nitrite: Negative	16 Participants	—	—
Period 1: Number of Participants With Urinalysis Dipstick Results Occult Blood: Negative	15 Participants	—	—
Period 1: Number of Participants With Urinalysis Dipstick Results Occult Blood: 2+	1 Participants	—	—
Period 1: Number of Participants With Urinalysis Dipstick Results Protein: Negative	16 Participants	—	—

SECONDARY outcome

Timeframe: Day 7

Population: Safety Population.

Urine samples were collected at indicated time points to analyze parameters including glucose, protein, occult blood, ketones, nitrite, bilirubin and leukocyte esterase levels by dipstick. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters can be read as negative, Trace, 1+ (low concentrations present), and 2+ (moderate concentrations present) indicating proportional concentrations in the urine sample.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Number of Participants With Urinalysis Dipstick Results Bilirubin: Negative	16 Participants	—	—
Period 2: Number of Participants With Urinalysis Dipstick Results Glucose: Negative	16 Participants	—	—
Period 2: Number of Participants With Urinalysis Dipstick Results Ketones: Negative	15 Participants	—	—
Period 2: Number of Participants With Urinalysis Dipstick Results Ketones: 1+	1 Participants	—	—
Period 2: Number of Participants With Urinalysis Dipstick Results Leukocyte Esterase: Negative	15 Participants	—	—
Period 2: Number of Participants With Urinalysis Dipstick Results Leukocyte Esterase: 1+	1 Participants	—	—
Period 2: Number of Participants With Urinalysis Dipstick Results Nitrite: Negative	16 Participants	—	—
Period 2: Number of Participants With Urinalysis Dipstick Results Occult Blood: Negative	16 Participants	—	—
Period 2: Number of Participants With Urinalysis Dipstick Results Protein: Negative	16 Participants	—	—

SECONDARY outcome

Timeframe: Days 4, 7 and 10

Population: Safety Population.

Urine samples were collected at indicated time points to analyze parameters including glucose, protein, occult blood, ketones, nitrite, bilirubin and leukocyte esterase levels by dipstick. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters can be read as negative, Trace, 1+ (low concentrations present), and 2+ (moderate concentrations present)indicating proportional concentrations in the urine sample.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Number of Participants With Urinalysis Dipstick Results Ketones: Day 10, Negative	16 Participants	—	—
Period 3: Number of Participants With Urinalysis Dipstick Results Protein: Day 4, Negative	16 Participants	—	—
Period 3: Number of Participants With Urinalysis Dipstick Results Protein: Day 7, Negative	16 Participants	—	—
Period 3: Number of Participants With Urinalysis Dipstick Results Bilirubin: Day 4, Negative	16 Participants	—	—
Period 3: Number of Participants With Urinalysis Dipstick Results Bilirubin: Day 7, Negative	16 Participants	—	—
Period 3: Number of Participants With Urinalysis Dipstick Results Bilirubin: Day 10, Negative	16 Participants	—	—
Period 3: Number of Participants With Urinalysis Dipstick Results Glucose: Day 4, Negative	16 Participants	—	—
Period 3: Number of Participants With Urinalysis Dipstick Results Glucose: Day 7, Negative	16 Participants	—	—
Period 3: Number of Participants With Urinalysis Dipstick Results Glucose: Day 10, Negative	16 Participants	—	—
Period 3: Number of Participants With Urinalysis Dipstick Results Ketones: Day 4, Negative	16 Participants	—	—
Period 3: Number of Participants With Urinalysis Dipstick Results Ketones: Day 7, Negative	16 Participants	—	—
Period 3: Number of Participants With Urinalysis Dipstick Results Leukocyte Esterase: Day 4, Negative	16 Participants	—	—
Period 3: Number of Participants With Urinalysis Dipstick Results Leukocyte Esterase: Day 7, Negative	16 Participants	—	—
Period 3: Number of Participants With Urinalysis Dipstick Results Leukocyte Esterase: Day 10, Negative	16 Participants	—	—
Period 3: Number of Participants With Urinalysis Dipstick Results Nitrite: Day 4, Negative	16 Participants	—	—
Period 3: Number of Participants With Urinalysis Dipstick Results Nitrite: Day 7, Negative	16 Participants	—	—
Period 3: Number of Participants With Urinalysis Dipstick Results Nitrite: Day 10, Negative	16 Participants	—	—
Period 3: Number of Participants With Urinalysis Dipstick Results Occult Blood: Day 4, Negative	16 Participants	—	—
Period 3: Number of Participants With Urinalysis Dipstick Results Occult Blood: Day 7, Negative	16 Participants	—	—
Period 3: Number of Participants With Urinalysis Dipstick Results Occult Blood: Day 10, Negative	16 Participants	—	—
Period 3: Number of Participants With Urinalysis Dipstick Results Protein: Day 10, Negative	16 Participants	—	—

SECONDARY outcome

Timeframe: Baseline, Day 1: 2 hours, 4 hours; Day 5: Pre-dose, 2 hours and 4 hours

Population: Safety Population.

Twelve-lead electrocardiograms (ECG) were obtained to measure PR Interval, QRS Duration, QT Interval, QTcF Interval and QTcB Interval. Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes. Baseline was defined as the average of the triplicate pre-dose assessments on Day 1 of Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Change From Baseline in PR Interval, QRS Duration, QT Interval, Fridericia QT Correction Formula (QTcF), Bazett's QT Correction Formula (QTcB) PR Interval: Day 5, 2 hours	1.3 Milliseconds Standard Deviation 8.52	—	—
Period 1: Change From Baseline in PR Interval, QRS Duration, QT Interval, Fridericia QT Correction Formula (QTcF), Bazett's QT Correction Formula (QTcB) PR Interval: Day 5, 4 hours	1.9 Milliseconds Standard Deviation 12.94	—	—
Period 1: Change From Baseline in PR Interval, QRS Duration, QT Interval, Fridericia QT Correction Formula (QTcF), Bazett's QT Correction Formula (QTcB) QRS Duration: Day 5, 2 hours	0.8 Milliseconds Standard Deviation 3.99	—	—
Period 1: Change From Baseline in PR Interval, QRS Duration, QT Interval, Fridericia QT Correction Formula (QTcF), Bazett's QT Correction Formula (QTcB) QRS Duration: Day 5, 4 hours	0.6 Milliseconds Standard Deviation 2.78	—	—
Period 1: Change From Baseline in PR Interval, QRS Duration, QT Interval, Fridericia QT Correction Formula (QTcF), Bazett's QT Correction Formula (QTcB) QT Interval: Day 1, 2 hours	-5.5 Milliseconds Standard Deviation 8.21	—	—
Period 1: Change From Baseline in PR Interval, QRS Duration, QT Interval, Fridericia QT Correction Formula (QTcF), Bazett's QT Correction Formula (QTcB) QT Interval: Day 1, 4 hours	9.9 Milliseconds Standard Deviation 12.91	—	—
Period 1: Change From Baseline in PR Interval, QRS Duration, QT Interval, Fridericia QT Correction Formula (QTcF), Bazett's QT Correction Formula (QTcB) QT Interval: Day 5, 2 hours	-16.3 Milliseconds Standard Deviation 16.64	—	—
Period 1: Change From Baseline in PR Interval, QRS Duration, QT Interval, Fridericia QT Correction Formula (QTcF), Bazett's QT Correction Formula (QTcB) QT Interval: Day 5, 4 hours	1.2 Milliseconds Standard Deviation 16.07	—	—
Period 1: Change From Baseline in PR Interval, QRS Duration, QT Interval, Fridericia QT Correction Formula (QTcF), Bazett's QT Correction Formula (QTcB) QTcF Interval: Day 5, Pre-dose	-7.1 Milliseconds Standard Deviation 8.53	—	—
Period 1: Change From Baseline in PR Interval, QRS Duration, QT Interval, Fridericia QT Correction Formula (QTcF), Bazett's QT Correction Formula (QTcB) QTcB Interval: Day 1, 2 hours	-4.5 Milliseconds Standard Deviation 10.26	—	—
Period 1: Change From Baseline in PR Interval, QRS Duration, QT Interval, Fridericia QT Correction Formula (QTcF), Bazett's QT Correction Formula (QTcB) QTcB Interval: Day 1, 4 hours	-7.4 Milliseconds Standard Deviation 9.16	—	—
Period 1: Change From Baseline in PR Interval, QRS Duration, QT Interval, Fridericia QT Correction Formula (QTcF), Bazett's QT Correction Formula (QTcB) QTcB Interval: Day 5, Pre-dose	-6.7 Milliseconds Standard Deviation 8.16	—	—
Period 1: Change From Baseline in PR Interval, QRS Duration, QT Interval, Fridericia QT Correction Formula (QTcF), Bazett's QT Correction Formula (QTcB) QTcB Interval: Day 5, 2 hours	-3.4 Milliseconds Standard Deviation 10.84	—	—
Period 1: Change From Baseline in PR Interval, QRS Duration, QT Interval, Fridericia QT Correction Formula (QTcF), Bazett's QT Correction Formula (QTcB) PR Interval: Day 1, 2 hours	-0.5 Milliseconds Standard Deviation 9.33	—	—
Period 1: Change From Baseline in PR Interval, QRS Duration, QT Interval, Fridericia QT Correction Formula (QTcF), Bazett's QT Correction Formula (QTcB) PR Interval: Day 1, 4 hours	1.7 Milliseconds Standard Deviation 8.34	—	—
Period 1: Change From Baseline in PR Interval, QRS Duration, QT Interval, Fridericia QT Correction Formula (QTcF), Bazett's QT Correction Formula (QTcB) PR Interval: Day 5, Pre-dose	4.7 Milliseconds Standard Deviation 6.32	—	—
Period 1: Change From Baseline in PR Interval, QRS Duration, QT Interval, Fridericia QT Correction Formula (QTcF), Bazett's QT Correction Formula (QTcB) QRS Duration: Day 1, 2 hours	1.8 Milliseconds Standard Deviation 3.04	—	—
Period 1: Change From Baseline in PR Interval, QRS Duration, QT Interval, Fridericia QT Correction Formula (QTcF), Bazett's QT Correction Formula (QTcB) QRS Duration: Day 1, 4 hours	1.3 Milliseconds Standard Deviation 3.32	—	—
Period 1: Change From Baseline in PR Interval, QRS Duration, QT Interval, Fridericia QT Correction Formula (QTcF), Bazett's QT Correction Formula (QTcB) QRS Duration: Day 5, Pre-dose	-0.8 Milliseconds Standard Deviation 3.21	—	—
Period 1: Change From Baseline in PR Interval, QRS Duration, QT Interval, Fridericia QT Correction Formula (QTcF), Bazett's QT Correction Formula (QTcB) QT Interval: Day 5, Pre-dose	-6.8 Milliseconds Standard Deviation 11.74	—	—
Period 1: Change From Baseline in PR Interval, QRS Duration, QT Interval, Fridericia QT Correction Formula (QTcF), Bazett's QT Correction Formula (QTcB) QTcF Interval: Day 1, 2 hours	-5.0 Milliseconds Standard Deviation 8.42	—	—
Period 1: Change From Baseline in PR Interval, QRS Duration, QT Interval, Fridericia QT Correction Formula (QTcF), Bazett's QT Correction Formula (QTcB) QTcF Interval: Day 1, 4 hours	-1.6 Milliseconds Standard Deviation 8.52	—	—
Period 1: Change From Baseline in PR Interval, QRS Duration, QT Interval, Fridericia QT Correction Formula (QTcF), Bazett's QT Correction Formula (QTcB) QTcF Interval: Day 5, 2 hours	-7.9 Milliseconds Standard Deviation 9.92	—	—
Period 1: Change From Baseline in PR Interval, QRS Duration, QT Interval, Fridericia QT Correction Formula (QTcF), Bazett's QT Correction Formula (QTcB) QTcF Interval: Day 5, 4 hours	-3.9 Milliseconds Standard Deviation 7.56	—	—
Period 1: Change From Baseline in PR Interval, QRS Duration, QT Interval, Fridericia QT Correction Formula (QTcF), Bazett's QT Correction Formula (QTcB) QTcB Interval: Day 5, 4 hours	-5.9 Milliseconds Standard Deviation 11.62	—	—

SECONDARY outcome

Timeframe: Baseline; Day 1: 2 hours, 4 hours; Day 5: Pre-dose, 2 hours and 4 hours

Population: Safety Population.

Twelve-lead ECG were obtained to measure PR Interval, QRS Duration, QT Interval, QTcF Interval and QTcB Interval. Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes. Baseline was defined as the average of the triplicate pre-dose assessments on Day 1 of Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcF Interval: Day 5, 2 hours	3.7 Milliseconds Standard Deviation 9.36	—	—
Period 2: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcF Interval: Day 5, 4 hours	10.2 Milliseconds Standard Deviation 10.44	—	—
Period 2: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcB Interval: Day 1, 2 hours	2.4 Milliseconds Standard Deviation 13.45	—	—
Period 2: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcB Interval: Day 1, 4 hours	2.6 Milliseconds Standard Deviation 12.62	—	—
Period 2: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcB Interval: Day 5, Pre-dose	8.4 Milliseconds Standard Deviation 5.92	—	—
Period 2: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcB Interval: Day 5, 2 hours	9.9 Milliseconds Standard Deviation 11.93	—	—
Period 2: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QRS Duration: Day 5, 4 hours	0.6 Milliseconds Standard Deviation 2.70	—	—
Period 2: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QT Interval: Day 1, 2 hours	-7.9 Milliseconds Standard Deviation 11.47	—	—
Period 2: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QT Interval: Day 5, Pre-dose	2.8 Milliseconds Standard Deviation 17.38	—	—
Period 2: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QT Interval: Day 5, 2 hours	-7.1 Milliseconds Standard Deviation 16.13	—	—
Period 2: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcF Interval: Day 1, 4 hours	3.1 Milliseconds Standard Deviation 6.44	—	—
Period 2: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcF Interval: Day 5, Pre-dose	6.6 Milliseconds Standard Deviation 6.79	—	—
Period 2: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB PR Interval: Day 1, 2 hours	-3.3 Milliseconds Standard Deviation 6.31	—	—
Period 2: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB PR Interval: Day 1, 4 hours	-3.0 Milliseconds Standard Deviation 5.55	—	—
Period 2: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB PR Interval: Day 5, Pre-dose	-2.1 Milliseconds Standard Deviation 6.15	—	—
Period 2: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB PR Interval: Day 5, 2 hours	-3.4 Milliseconds Standard Deviation 7.81	—	—
Period 2: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB PR Interval: Day 5, 4 hours	-6.4 Milliseconds Standard Deviation 6.77	—	—
Period 2: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QRS Duration: Day 1, 2 hours	0.1 Milliseconds Standard Deviation 2.54	—	—
Period 2: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QRS Duration: Day 1, 4 hours	-1.1 Milliseconds Standard Deviation 4.08	—	—
Period 2: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QRS Duration: Day 5, Pre-dose	0.3 Milliseconds Standard Deviation 3.89	—	—
Period 2: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QRS Duration: Day 5, 2 hours	-0.2 Milliseconds Standard Deviation 3.85	—	—
Period 2: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QT Interval: Day 1, 4 hours	4.6 Milliseconds Standard Deviation 13.48	—	—
Period 2: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QT Interval: Day 5, 4 hours	6.3 Milliseconds Standard Deviation 20.51	—	—
Period 2: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcF Interval: Day 1, 2 hours	-1.3 Milliseconds Standard Deviation 8.74	—	—
Period 2: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcB Interval: Day 5, 4 hours	12.4 Milliseconds Standard Deviation 8.57	—	—

SECONDARY outcome

Timeframe: Baseline; Day 1: 2 hours, 4 hours; Days 4, 5 and 7: Pre-dose, 2 hours and 4 hours; Day 10

Population: Safety Population.

Twelve-lead ECG were obtained to measure PR Interval, QRS Duration, QT Interval, QTcF Interval and QTcB Interval. Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QRS Duration: Day 1, 4 hours	-2.1 Milliseconds Standard Deviation 3.80	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB PR Interval: Day 1, 4 hours	-1.9 Milliseconds Standard Deviation 8.19	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB PR Interval: Day 5, 4 hours	-2.7 Milliseconds Standard Deviation 7.77	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QT Interval: Day 1, 2 hours	-7.8 Milliseconds Standard Deviation 8.68	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcF Interval: Day 5, 2 hours	1.1 Milliseconds Standard Deviation 9.42	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcF Interval: Day 7, 4 hours	3.6 Milliseconds Standard Deviation 7.28	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcF Interval: Day 10	1.6 Milliseconds Standard Deviation 7.36	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcB Interval: Day 1, 2 hours	3.8 Milliseconds Standard Deviation 9.50	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcB Interval: Day 1, 4 hours	7.4 Milliseconds Standard Deviation 10.78	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcB Interval: Day 4, Pre-dose	3.8 Milliseconds Standard Deviation 13.72	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcB Interval: Day 4, 2 hours	-0.6 Milliseconds Standard Deviation 17.78	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcB Interval: Day 4, 4 hours	8.6 Milliseconds Standard Deviation 12.83	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcB Interval: Day 5, Pre-dose	10.6 Milliseconds Standard Deviation 13.25	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcB Interval: Day 5, 2 hours	5.5 Milliseconds Standard Deviation 12.47	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcB Interval: Day 5, 4 hours	11.3 Milliseconds Standard Deviation 9.50	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcB Interval: Day 7, Pre-dose	2.1 Milliseconds Standard Deviation 14.09	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcB Interval: Day 7, 2 hours	4.4 Milliseconds Standard Deviation 14.43	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcB Interval: Day 7, 4 hours	1.4 Milliseconds Standard Deviation 10.35	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcB Interval: Day 10	0.2 Milliseconds Standard Deviation 10.89	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB PR Interval: Day 1, 2 hours	1.9 Milliseconds Standard Deviation 7.47	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB PR Interval: Day 4, Pre-dose	-0.4 Milliseconds Standard Deviation 6.97	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB PR Interval: Day 4, 2 hours	0.9 Milliseconds Standard Deviation 8.48	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB PR Interval: Day 4, 4 hours	-2.9 Milliseconds Standard Deviation 9.53	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB PR Interval: Day 5, Pre-dose	-1.4 Milliseconds Standard Deviation 10.59	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB PR Interval: Day 5, 2 hours	-3.2 Milliseconds Standard Deviation 9.13	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB PR Interval: Day 7, Pre-dose	3.6 Milliseconds Standard Deviation 7.61	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB PR Interval: Day 7, 2 hours	-1.0 Milliseconds Standard Deviation 9.47	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB PR Interval: Day 7, 4 hours	-0.4 Milliseconds Standard Deviation 7.61	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB PR Interval: Day 10	2.3 Milliseconds Standard Deviation 8.60	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QRS Duration: Day 1, 2 hours	1.1 Milliseconds Standard Deviation 5.47	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QRS Duration: Day 4, Pre-dose	2.0 Milliseconds Standard Deviation 5.61	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QRS Duration: Day 4, 2 hours	-1.3 Milliseconds Standard Deviation 3.09	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QRS Duration: Day 4, 4 hours	0.5 Milliseconds Standard Deviation 6.63	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QRS Duration: Day 5, Pre-dose	1.8 Milliseconds Standard Deviation 6.18	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QRS Duration: Day 5, 2 hours	1.3 Milliseconds Standard Deviation 5.11	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QRS Duration: Day 5, 4 hours	-0.5 Milliseconds Standard Deviation 3.31	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QRS Duration: Day 7, Pre-dose	0.6 Milliseconds Standard Deviation 3.58	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QRS Duration: Day 7, 2 hours	0.3 Milliseconds Standard Deviation 4.93	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QRS Duration: Day 7, 4 hours	-0.4 Milliseconds Standard Deviation 3.72	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QRS Duration: Day 10	1.7 Milliseconds Standard Deviation 5.45	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QT Interval: Day 1, 4 hours	4.4 Milliseconds Standard Deviation 13.15	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QT Interval: Day 4, Pre-dose	1.4 Milliseconds Standard Deviation 14.28	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QT Interval: Day 4, 2 hours	-11.2 Milliseconds Standard Deviation 14.53	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QT Interval: Day 4, 4 hours	7.4 Milliseconds Standard Deviation 13.68	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QT Interval: Day 5, Pre-dose	-1.4 Milliseconds Standard Deviation 13.57	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QT Interval: Day 5, 2 hours	-6.9 Milliseconds Standard Deviation 10.65	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QT Interval: Day 5, 4 hours	3.9 Milliseconds Standard Deviation 14.59	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QT Interval: Day 7, Pre-dose	3.2 Milliseconds Standard Deviation 17.34	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QT Interval: Day 7, 2 hours	-5.6 Milliseconds Standard Deviation 14.01	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QT Interval: Day 7, 4 hours	8.0 Milliseconds Standard Deviation 15.38	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QT Interval: Day 10	5.1 Milliseconds Standard Deviation 10.39	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcF Interval: Day 1, 2 hours	-0.4 Milliseconds Standard Deviation 5.63	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcF Interval: Day 1, 4 hours	6.6 Milliseconds Standard Deviation 4.97	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcF Interval: Day 4, Pre-dose	2.7 Milliseconds Standard Deviation 8.21	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcF Interval: Day 4, 2 hours	-2.5 Milliseconds Standard Deviation 8.41	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcF Interval: Day 4, 4 hours	8.1 Milliseconds Standard Deviation 9.10	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcF Interval: Day 5, Pre-dose	6.1 Milliseconds Standard Deviation 8.14	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcF Interval: Day 5, 4 hours	8.6 Milliseconds Standard Deviation 6.26	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcF Interval: Day 7, Pre-dose	2.0 Milliseconds Standard Deviation 9.21	—	—
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcF Interval: Day 7, 2 hours	0.6 Milliseconds Standard Deviation 7.46	—	—

SECONDARY outcome

Timeframe: Baseline (Day 1, Pre-dose), Days 2, 3, 4 and 5

Population: Safety Population.

SBP and DBP were measured in the semi-recumbent position with a completely automated device. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP: Day 2	3.5 Millimeters of mercury Standard Deviation 9.97	—	—
Period 1: Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP: Day 3	-0.4 Millimeters of mercury Standard Deviation 8.88	—	—
Period 1: Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP: Day 4	3.7 Millimeters of mercury Standard Deviation 11.97	—	—
Period 1: Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP: Day 5	-6.2 Millimeters of mercury Standard Deviation 8.88	—	—
Period 1: Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP: Day 2	4.3 Millimeters of mercury Standard Deviation 6.70	—	—
Period 1: Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP: Day 3	0.9 Millimeters of mercury Standard Deviation 9.89	—	—
Period 1: Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP: Day 4	2.3 Millimeters of mercury Standard Deviation 8.50	—	—
Period 1: Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP: Day 5	-2.6 Millimeters of mercury Standard Deviation 10.70	—	—

SECONDARY outcome

Timeframe: Baseline (Day 1, Pre-dose), Days 2, 3, 4, 5, 6 and 7

Population: Safety Population.

SBP and DBP were measured in the semi-recumbent position with a completely automated device. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Change From Baseline in SBP and DBP SBP: Day 6	-0.1 Millimeters of mercury Standard Deviation 8.01	—	—
Period 2: Change From Baseline in SBP and DBP SBP: Day 7	0.6 Millimeters of mercury Standard Deviation 4.57	—	—
Period 2: Change From Baseline in SBP and DBP DBP: Day 2	-0.4 Millimeters of mercury Standard Deviation 7.03	—	—
Period 2: Change From Baseline in SBP and DBP DBP: Day 3	1.1 Millimeters of mercury Standard Deviation 4.46	—	—
Period 2: Change From Baseline in SBP and DBP DBP: Day 4	-0.4 Millimeters of mercury Standard Deviation 4.67	—	—
Period 2: Change From Baseline in SBP and DBP DBP: Day 5	-1.3 Millimeters of mercury Standard Deviation 4.85	—	—
Period 2: Change From Baseline in SBP and DBP DBP: Day 6	0.3 Millimeters of mercury Standard Deviation 6.37	—	—
Period 2: Change From Baseline in SBP and DBP SBP: Day 2	1.7 Millimeters of mercury Standard Deviation 5.19	—	—
Period 2: Change From Baseline in SBP and DBP SBP: Day 3	1.3 Millimeters of mercury Standard Deviation 6.83	—	—
Period 2: Change From Baseline in SBP and DBP SBP: Day 4	3.0 Millimeters of mercury Standard Deviation 7.73	—	—
Period 2: Change From Baseline in SBP and DBP SBP: Day 5	-0.5 Millimeters of mercury Standard Deviation 5.40	—	—
Period 2: Change From Baseline in SBP and DBP DBP: Day 7	0.4 Millimeters of mercury Standard Deviation 5.62	—	—

SECONDARY outcome

Timeframe: Baseline (Day 1, Pre-dose), Days 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11

Population: Safety Population.

SBP and DBP were measured in the semi-recumbent position with a completely automated device. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Change From Baseline in SBP and DBP DBP: Day 4	1.2 Millimeters of mercury Standard Deviation 4.51	—	—
Period 3: Change From Baseline in SBP and DBP SBP: Day 2	-0.1 Millimeters of mercury Standard Deviation 7.66	—	—
Period 3: Change From Baseline in SBP and DBP SBP: Day 3	-3.4 Millimeters of mercury Standard Deviation 6.54	—	—
Period 3: Change From Baseline in SBP and DBP SBP: Day 4	-3.3 Millimeters of mercury Standard Deviation 6.63	—	—
Period 3: Change From Baseline in SBP and DBP SBP: Day 5	3.6 Millimeters of mercury Standard Deviation 17.17	—	—
Period 3: Change From Baseline in SBP and DBP SBP: Day 6	-1.4 Millimeters of mercury Standard Deviation 7.08	—	—
Period 3: Change From Baseline in SBP and DBP SBP: Day 7	-2.1 Millimeters of mercury Standard Deviation 7.76	—	—
Period 3: Change From Baseline in SBP and DBP SBP: Day 8	-2.0 Millimeters of mercury Standard Deviation 9.36	—	—
Period 3: Change From Baseline in SBP and DBP SBP: Day 9	-2.3 Millimeters of mercury Standard Deviation 8.00	—	—
Period 3: Change From Baseline in SBP and DBP SBP: Day 10	-4.3 Millimeters of mercury Standard Deviation 8.35	—	—
Period 3: Change From Baseline in SBP and DBP SBP: Day 11	-3.4 Millimeters of mercury Standard Deviation 7.69	—	—
Period 3: Change From Baseline in SBP and DBP DBP: Day 2	1.3 Millimeters of mercury Standard Deviation 3.32	—	—
Period 3: Change From Baseline in SBP and DBP DBP: Day 3	-0.1 Millimeters of mercury Standard Deviation 5.73	—	—
Period 3: Change From Baseline in SBP and DBP DBP: Day 5	6.7 Millimeters of mercury Standard Deviation 22.20	—	—
Period 3: Change From Baseline in SBP and DBP DBP: Day 6	1.4 Millimeters of mercury Standard Deviation 6.99	—	—
Period 3: Change From Baseline in SBP and DBP DBP: Day 7	2.9 Millimeters of mercury Standard Deviation 5.88	—	—
Period 3: Change From Baseline in SBP and DBP DBP: Day 8	1.8 Millimeters of mercury Standard Deviation 9.89	—	—
Period 3: Change From Baseline in SBP and DBP DBP: Day 9	2.1 Millimeters of mercury Standard Deviation 5.87	—	—
Period 3: Change From Baseline in SBP and DBP DBP: Day 10	2.3 Millimeters of mercury Standard Deviation 4.91	—	—
Period 3: Change From Baseline in SBP and DBP DBP: Day 11	-0.1 Millimeters of mercury Standard Deviation 5.43	—	—

SECONDARY outcome

Timeframe: Baseline (Day 1, Pre-dose), Days 2, 3, 4 and 5

Population: Safety Population.

Pulse rate was measured in the semi-recumbent position with a completely automated device. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Change From Baseline in Pulse Rate Day 4	2.0 Beats per minute Standard Deviation 8.46	—	—
Period 1: Change From Baseline in Pulse Rate Day 5	-1.6 Beats per minute Standard Deviation 5.08	—	—
Period 1: Change From Baseline in Pulse Rate Day 2	-0.3 Beats per minute Standard Deviation 4.30	—	—
Period 1: Change From Baseline in Pulse Rate Day 3	-1.3 Beats per minute Standard Deviation 4.63	—	—

SECONDARY outcome

Timeframe: Baseline (Day 1, Pre-dose), Days 2, 3, 4, 5, 6 and 7

Population: Safety Population.

Pulse rate was measured in the semi-recumbent position with a completely automated device. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Change From Baseline in Pulse Rate Day 2	3.9 Beats per minute Standard Deviation 8.54	—	—
Period 2: Change From Baseline in Pulse Rate Day 3	5.4 Beats per minute Standard Deviation 7.19	—	—
Period 2: Change From Baseline in Pulse Rate Day 4	4.8 Beats per minute Standard Deviation 7.50	—	—
Period 2: Change From Baseline in Pulse Rate Day 5	4.2 Beats per minute Standard Deviation 8.73	—	—
Period 2: Change From Baseline in Pulse Rate Day 6	3.8 Beats per minute Standard Deviation 6.51	—	—
Period 2: Change From Baseline in Pulse Rate Day 7	2.7 Beats per minute Standard Deviation 5.78	—	—

SECONDARY outcome

Timeframe: Baseline (Day 1, Pre-dose), Days 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11

Population: Safety Population.

Pulse rate was measured in the semi-recumbent position with a completely automated device. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Change From Baseline in Pulse Rate Day 4	0.3 Beats per minute Standard Deviation 7.63	—	—
Period 3: Change From Baseline in Pulse Rate Day 5	3.1 Beats per minute Standard Deviation 7.79	—	—
Period 3: Change From Baseline in Pulse Rate Day 8	2.3 Beats per minute Standard Deviation 9.34	—	—
Period 3: Change From Baseline in Pulse Rate Day 9	-0.8 Beats per minute Standard Deviation 7.90	—	—
Period 3: Change From Baseline in Pulse Rate Day 2	1.8 Beats per minute Standard Deviation 5.65	—	—
Period 3: Change From Baseline in Pulse Rate Day 3	2.2 Beats per minute Standard Deviation 6.88	—	—
Period 3: Change From Baseline in Pulse Rate Day 6	1.3 Beats per minute Standard Deviation 6.97	—	—
Period 3: Change From Baseline in Pulse Rate Day 7	-2.1 Beats per minute Standard Deviation 5.94	—	—
Period 3: Change From Baseline in Pulse Rate Day 10	-2.9 Beats per minute Standard Deviation 5.34	—	—
Period 3: Change From Baseline in Pulse Rate Day 11	1.7 Beats per minute Standard Deviation 10.56	—	—

SECONDARY outcome

Timeframe: Baseline (Day 1, Pre-dose), Days 2, 3, 4 and 5

Population: Safety Population.

Respiratory rate was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Change From Baseline in Respiratory Rate Day 2	-0.9 Breaths per minute Standard Deviation 3.18	—	—
Period 1: Change From Baseline in Respiratory Rate Day 3	0.3 Breaths per minute Standard Deviation 2.05	—	—
Period 1: Change From Baseline in Respiratory Rate Day 4	-1.5 Breaths per minute Standard Deviation 3.06	—	—
Period 1: Change From Baseline in Respiratory Rate Day 5	-0.8 Breaths per minute Standard Deviation 2.29	—	—

SECONDARY outcome

Timeframe: Baseline (Day 1, Pre-dose), Days 2, 3, 4, 5, 6 and 7

Population: Safety Population. Only those participants with data available at the indicated time points were analyzed (represented by n= X in the category titles).

Respiratory rate was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Change From Baseline in Respiratory Rate Day 2, n=16	-0.5 Breaths per minute Standard Deviation 2.58	—	—
Period 2: Change From Baseline in Respiratory Rate Day 3, n=16	0.4 Breaths per minute Standard Deviation 3.03	—	—
Period 2: Change From Baseline in Respiratory Rate Day 4, n=16	-0.6 Breaths per minute Standard Deviation 3.07	—	—
Period 2: Change From Baseline in Respiratory Rate Day 5, n=15	1.3 Breaths per minute Standard Deviation 2.47	—	—
Period 2: Change From Baseline in Respiratory Rate Day 6, n=16	-0.4 Breaths per minute Standard Deviation 2.55	—	—
Period 2: Change From Baseline in Respiratory Rate Day 7, n=16	0.1 Breaths per minute Standard Deviation 3.30	—	—

SECONDARY outcome

Timeframe: Baseline (Day 1, Pre-dose), Days 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11

Population: Safety Population.

Respiratory rate was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Change From Baseline in Respiratory Rate Day 6	0.6 Breaths per minute Standard Deviation 3.24	—	—
Period 3: Change From Baseline in Respiratory Rate Day 2	1.4 Breaths per minute Standard Deviation 3.07	—	—
Period 3: Change From Baseline in Respiratory Rate Day 3	0.5 Breaths per minute Standard Deviation 3.39	—	—
Period 3: Change From Baseline in Respiratory Rate Day 4	0.3 Breaths per minute Standard Deviation 3.34	—	—
Period 3: Change From Baseline in Respiratory Rate Day 5	-0.5 Breaths per minute Standard Deviation 2.97	—	—
Period 3: Change From Baseline in Respiratory Rate Day 7	0.3 Breaths per minute Standard Deviation 3.09	—	—
Period 3: Change From Baseline in Respiratory Rate Day 8	1.4 Breaths per minute Standard Deviation 2.80	—	—
Period 3: Change From Baseline in Respiratory Rate Day 9	-0.4 Breaths per minute Standard Deviation 3.36	—	—
Period 3: Change From Baseline in Respiratory Rate Day 10	1.4 Breaths per minute Standard Deviation 2.80	—	—
Period 3: Change From Baseline in Respiratory Rate Day 11	2.8 Breaths per minute Standard Deviation 2.41	—	—

SECONDARY outcome

Timeframe: Baseline (Day 1, Pre-dose), Days 2, 3, 4 and 5

Population: Safety Population.

Body temperature was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Change From Baseline in Body Temperature Day 2	-0.04 Degrees Celsius Standard Deviation 0.326	—	—
Period 1: Change From Baseline in Body Temperature Day 3	-0.14 Degrees Celsius Standard Deviation 0.287	—	—
Period 1: Change From Baseline in Body Temperature Day 4	-0.19 Degrees Celsius Standard Deviation 0.370	—	—
Period 1: Change From Baseline in Body Temperature Day 5	0.03 Degrees Celsius Standard Deviation 0.275	—	—

SECONDARY outcome

Timeframe: Baseline (Day 1, Pre-dose), Days 2, 3, 4, 5, 6 and 7

Population: Safety Population.

Body temperature was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Change From Baseline in Body Temperature Day 2	-0.14 Degrees Celsius Standard Deviation 0.299	—	—
Period 2: Change From Baseline in Body Temperature Day 3	-0.25 Degrees Celsius Standard Deviation 0.415	—	—
Period 2: Change From Baseline in Body Temperature Day 4	-0.19 Degrees Celsius Standard Deviation 0.294	—	—
Period 2: Change From Baseline in Body Temperature Day 5	-0.05 Degrees Celsius Standard Deviation 0.363	—	—
Period 2: Change From Baseline in Body Temperature Day 6	-0.13 Degrees Celsius Standard Deviation 0.300	—	—
Period 2: Change From Baseline in Body Temperature Day 7	-0.13 Degrees Celsius Standard Deviation 0.373	—	—

SECONDARY outcome

Timeframe: Baseline (Day 1, Pre-dose), Days 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11

Population: Safety Population.

Body temperature was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Change From Baseline in Body Temperature Day 4	0.02 Degrees Celsius Standard Deviation 0.229	—	—
Period 3: Change From Baseline in Body Temperature Day 9	-0.10 Degrees Celsius Standard Deviation 0.329	—	—
Period 3: Change From Baseline in Body Temperature Day 10	-0.03 Degrees Celsius Standard Deviation 0.291	—	—
Period 3: Change From Baseline in Body Temperature Day 2	-0.08 Degrees Celsius Standard Deviation 0.286	—	—
Period 3: Change From Baseline in Body Temperature Day 3	-0.18 Degrees Celsius Standard Deviation 0.423	—	—
Period 3: Change From Baseline in Body Temperature Day 5	0.00 Degrees Celsius Standard Deviation 0.175	—	—
Period 3: Change From Baseline in Body Temperature Day 6	-0.03 Degrees Celsius Standard Deviation 0.318	—	—
Period 3: Change From Baseline in Body Temperature Day 7	0.06 Degrees Celsius Standard Deviation 0.287	—	—
Period 3: Change From Baseline in Body Temperature Day 8	-0.13 Degrees Celsius Standard Deviation 0.458	—	—
Period 3: Change From Baseline in Body Temperature Day 11	0.13 Degrees Celsius Standard Deviation 0.302	—	—

SECONDARY outcome

Timeframe: Day 9

Population: Safety Population.

Blood samples were collected to analyze the hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelet count.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Basophils	0.045 10^9 cells per liter Standard Deviation 0.0115	—	—
Period 1: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Eosinophils	0.232 10^9 cells per liter Standard Deviation 0.1440	—	—
Period 1: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Lymphocytes	2.023 10^9 cells per liter Standard Deviation 0.5931	—	—
Period 1: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Monocytes	0.512 10^9 cells per liter Standard Deviation 0.1133	—	—
Period 1: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Neutrophils	3.038 10^9 cells per liter Standard Deviation 0.7559	—	—
Period 1: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Platelet count	270.2 10^9 cells per liter Standard Deviation 47.62	—	—

SECONDARY outcome

Timeframe: Day 7

Population: Safety Population.

Blood samples were collected to analyze the hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelet count.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Basophils	0.039 10^9 cells per liter Standard Deviation 0.0134	—	—
Period 2: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Eosinophils	0.206 10^9 cells per liter Standard Deviation 0.0960	—	—
Period 2: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Lymphocytes	1.869 10^9 cells per liter Standard Deviation 0.4383	—	—
Period 2: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Monocytes	0.488 10^9 cells per liter Standard Deviation 0.1081	—	—
Period 2: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Neutrophils	2.878 10^9 cells per liter Standard Deviation 0.6859	—	—
Period 2: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Platelet count	264.2 10^9 cells per liter Standard Deviation 48.37	—	—

SECONDARY outcome

Timeframe: Days 4, 7 and 10

Population: Safety Population. Only those participants with data available at the indicated time points were analyzed (represented by n= X in the category titles).

Blood samples were collected to analyze the hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelet count.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Day 10: Lymphocytes, n=16	1.753 10^9 cells per liter Standard Deviation 0.3450	—	—
Period 3: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Day 4: Monocytes, n=16	0.537 10^9 cells per liter Standard Deviation 0.1821	—	—
Period 3: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Day 4: Basophils, n=16	0.043 10^9 cells per liter Standard Deviation 0.0165	—	—
Period 3: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Day 7: Basophils, n=16	0.046 10^9 cells per liter Standard Deviation 0.0196	—	—
Period 3: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Day 10: Basophils, n=16	0.042 10^9 cells per liter Standard Deviation 0.0142	—	—
Period 3: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Day 4: Eosinophils, n=16	0.206 10^9 cells per liter Standard Deviation 0.1120	—	—
Period 3: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Day 7: Eosinophils, n=16	0.211 10^9 cells per liter Standard Deviation 0.1512	—	—
Period 3: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Day 10: Eosinophils, n=16	0.171 10^9 cells per liter Standard Deviation 0.0874	—	—
Period 3: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Day 4: Lymphocytes, n=16	1.739 10^9 cells per liter Standard Deviation 0.3701	—	—
Period 3: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Day 7: Lymphocytes, n=16	1.837 10^9 cells per liter Standard Deviation 0.3916	—	—
Period 3: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Day 7: Monocytes, n=16	0.490 10^9 cells per liter Standard Deviation 0.1157	—	—
Period 3: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Day 10: Monocytes, n=16	0.470 10^9 cells per liter Standard Deviation 0.1128	—	—
Period 3: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Day 4: Neutrophils, n=16	3.321 10^9 cells per liter Standard Deviation 1.4579	—	—
Period 3: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Day 7: Neutrophils, n=16	2.954 10^9 cells per liter Standard Deviation 0.5600	—	—
Period 3: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Day 10: Neutrophils, n=16	3.082 10^9 cells per liter Standard Deviation 0.6649	—	—
Period 3: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Day 4: Platelet count, n=16	259.3 10^9 cells per liter Standard Deviation 46.03	—	—
Period 3: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Day 7: Platelet count, n=15	255.3 10^9 cells per liter Standard Deviation 46.20	—	—
Period 3: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count Day 10: Platelet count, n=16	258.3 10^9 cells per liter Standard Deviation 42.92	—	—

SECONDARY outcome

Timeframe: Day 9

Population: Safety Population.

Blood samples were collected to analyze the hematology parameter: hemoglobin.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Absolute Values for Hematology Parameter: Hemoglobin	146.4 Grams per liter Standard Deviation 8.02	—	—

SECONDARY outcome

Timeframe: Day 7

Population: Safety Population.

Blood samples were collected to analyze the hematology parameter: hemoglobin.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Absolute Values for Hematology Parameter: Hemoglobin	146.5 Grams per liter Standard Deviation 8.68	—	—

SECONDARY outcome

Timeframe: Days 4, 7 and 10

Population: Safety Population.

Blood samples were collected to analyze the hematology parameter: hemoglobin.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Absolute Values for Hematology Parameter: Hemoglobin Day 4	149.8 Grams per liter Standard Deviation 8.74	—	—
Period 3: Absolute Values for Hematology Parameter: Hemoglobin Day 7	147.1 Grams per liter Standard Deviation 8.23	—	—
Period 3: Absolute Values for Hematology Parameter: Hemoglobin Day 10	147.7 Grams per liter Standard Deviation 9.17	—	—

SECONDARY outcome

Timeframe: Day 9

Population: Safety Population.

Blood samples were collected to analyze the hematology parameter: hematocrit.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Absolute Values for Hematology Parameter: Hematocrit	0.4419 Proportion of red blood cells in blood Standard Deviation 0.01697	—	—

SECONDARY outcome

Timeframe: Day 7

Population: Safety Population.

Blood samples were collected to analyze the hematology parameter: hematocrit.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Absolute Values for Hematology Parameter: Hematocrit	0.4406 Proportion of red blood cells in blood Standard Deviation 0.01887	—	—

SECONDARY outcome

Timeframe: Days 4, 7 and 10

Population: Safety Population.

Blood samples were collected to analyze the hematology parameter: hematocrit.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Absolute Values for Hematology Parameter: Hematocrit Day 4	0.4441 Proportion of red blood cells in blood Standard Deviation 0.01956	—	—
Period 3: Absolute Values for Hematology Parameter: Hematocrit Day 7	0.4357 Proportion of red blood cells in blood Standard Deviation 0.01924	—	—
Period 3: Absolute Values for Hematology Parameter: Hematocrit Day 10	0.4364 Proportion of red blood cells in blood Standard Deviation 0.02267	—	—

SECONDARY outcome

Timeframe: Day 9

Population: Safety Population.

Blood samples were collected to analyze the hematology parameter: erythrocytes.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Absolute Values for Hematology Parameter: Erythrocytes	5.143 Trillion cells per liter Standard Deviation 0.3580	—	—

SECONDARY outcome

Timeframe: Day 7

Population: Safety Population.

Blood samples were collected to analyze the hematology parameter: erythrocytes.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Absolute Values for Hematology Parameter: Erythrocytes	5.179 Trillion cells per liter Standard Deviation 0.3575	—	—

SECONDARY outcome

Timeframe: Days 4, 7 and 10

Population: Safety Population.

Blood samples were collected to analyze the hematology parameter: erythrocytes.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Absolute Values for Hematology Parameter: Erythrocytes Day 4	5.194 Trillion cells per liter Standard Deviation 0.3476	—	—
Period 3: Absolute Values for Hematology Parameter: Erythrocytes Day 7	5.099 Trillion cells per liter Standard Deviation 0.3798	—	—
Period 3: Absolute Values for Hematology Parameter: Erythrocytes Day 10	5.124 Trillion cells per liter Standard Deviation 0.3678	—	—

SECONDARY outcome

Timeframe: Day 9

Population: Safety Population.

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume	86.22 Femtoliter Standard Deviation 5.670	—	—

SECONDARY outcome

Timeframe: Day 7

Population: Safety Population.

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume	85.36 Femtoliter Standard Deviation 5.509	—	—

SECONDARY outcome

Timeframe: Days 4, 7 and 10

Population: Safety Population.

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume Day 4	85.76 Femtoliter Standard Deviation 5.323	—	—
Period 3: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume Day 7	85.72 Femtoliter Standard Deviation 5.117	—	—
Period 3: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume Day 10	85.41 Femtoliter Standard Deviation 5.030	—	—

SECONDARY outcome

Timeframe: Day 9

Population: Safety Population.

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin	28.58 Picograms Standard Deviation 2.446	—	—

SECONDARY outcome

Timeframe: Day 7

Population: Safety Population.

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin	28.41 Picograms Standard Deviation 2.385	—	—

SECONDARY outcome

Timeframe: Days 4, 7 and 10

Population: Safety Population.

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin Day 4	28.96 Picograms Standard Deviation 2.514	—	—
Period 3: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin Day 7	28.96 Picograms Standard Deviation 2.404	—	—
Period 3: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin Day 10	28.93 Picograms Standard Deviation 2.530	—	—

SECONDARY outcome

Timeframe: Day 9

Population: Safety Population.

Blood samples were collected to analyze the chemistry parameters: glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and blood urea nitrogen.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Glucose	5.165 Millimoles per liter Standard Deviation 0.4788	—	—
Period 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Cholesterol	4.456 Millimoles per liter Standard Deviation 0.6591	—	—
Period 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Triglycerides	1.107 Millimoles per liter Standard Deviation 0.5362	—	—
Period 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Anion gap	9.2 Millimoles per liter Standard Deviation 1.28	—	—
Period 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Calcium	2.393 Millimoles per liter Standard Deviation 0.0781	—	—
Period 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Carbon dioxide	30.5 Millimoles per liter Standard Deviation 1.15	—	—
Period 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Chloride	103.8 Millimoles per liter Standard Deviation 2.32	—	—
Period 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Phosphate	1.244 Millimoles per liter Standard Deviation 0.1658	—	—
Period 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Potassium	4.31 Millimoles per liter Standard Deviation 0.427	—	—
Period 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Sodium	139.3 Millimoles per liter Standard Deviation 2.52	—	—
Period 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Blood urea nitrogen	5.406 Millimoles per liter Standard Deviation 0.7575	—	—

SECONDARY outcome

Timeframe: Day 7

Population: Safety Population.

Blood samples were collected to analyze the chemistry parameters: glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and blood urea nitrogen.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Sodium	139.6 Millimoles per liter Standard Deviation 1.90	—	—
Period 2: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Glucose	4.916 Millimoles per liter Standard Deviation 0.4825	—	—
Period 2: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Cholesterol	4.187 Millimoles per liter Standard Deviation 0.6783	—	—
Period 2: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Triglycerides	1.194 Millimoles per liter Standard Deviation 0.7294	—	—
Period 2: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Anion gap	11.4 Millimoles per liter Standard Deviation 1.20	—	—
Period 2: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Calcium	2.406 Millimoles per liter Standard Deviation 0.0772	—	—
Period 2: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Carbon dioxide	29.3 Millimoles per liter Standard Deviation 1.57	—	—
Period 2: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Chloride	103.1 Millimoles per liter Standard Deviation 2.35	—	—
Period 2: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Phosphate	1.281 Millimoles per liter Standard Deviation 0.1510	—	—
Period 2: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Potassium	4.23 Millimoles per liter Standard Deviation 0.249	—	—
Period 2: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Blood urea nitrogen	5.065 Millimoles per liter Standard Deviation 0.6775	—	—

SECONDARY outcome

Timeframe: Days 4, 7 and 10

Population: Safety Population.

Blood samples were collected to analyze the chemistry parameters: glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and blood urea nitrogen.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 10: Glucose	4.849 Millimoles per liter Standard Deviation 0.3858	—	—
Period 3: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 4: Cholesterol	4.283 Millimoles per liter Standard Deviation 0.8001	—	—
Period 3: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 4: Calcium	2.404 Millimoles per liter Standard Deviation 0.0855	—	—
Period 3: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 10: Sodium	140.1 Millimoles per liter Standard Deviation 2.11	—	—
Period 3: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 10: Blood urea nitrogen	5.039 Millimoles per liter Standard Deviation 0.8264	—	—
Period 3: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 4: Glucose	4.978 Millimoles per liter Standard Deviation 0.4655	—	—
Period 3: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 7: Glucose	5.018 Millimoles per liter Standard Deviation 0.3977	—	—
Period 3: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 7: Cholesterol	4.179 Millimoles per liter Standard Deviation 0.7438	—	—
Period 3: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 10: Cholesterol	4.157 Millimoles per liter Standard Deviation 0.8037	—	—
Period 3: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 4: Triglycerides	1.228 Millimoles per liter Standard Deviation 0.6403	—	—
Period 3: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 7: Triglycerides	1.100 Millimoles per liter Standard Deviation 0.5887	—	—
Period 3: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 10: Triglycerides	1.289 Millimoles per liter Standard Deviation 0.6625	—	—
Period 3: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 4: Anion gap	7.3 Millimoles per liter Standard Deviation 1.01	—	—
Period 3: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 7: Anion gap	11.4 Millimoles per liter Standard Deviation 1.75	—	—
Period 3: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 10: Anion gap	12.1 Millimoles per liter Standard Deviation 1.31	—	—
Period 3: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 7: Calcium	2.433 Millimoles per liter Standard Deviation 0.0827	—	—
Period 3: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 10: Calcium	2.441 Millimoles per liter Standard Deviation 0.0681	—	—
Period 3: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 4: Carbon dioxide	30.2 Millimoles per liter Standard Deviation 1.56	—	—
Period 3: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 7: Carbon dioxide	29.4 Millimoles per liter Standard Deviation 1.15	—	—
Period 3: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 10: Carbon dioxide	30.3 Millimoles per liter Standard Deviation 1.53	—	—
Period 3: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 4: Chloride	103.8 Millimoles per liter Standard Deviation 2.77	—	—
Period 3: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 7: Chloride	102.8 Millimoles per liter Standard Deviation 2.07	—	—
Period 3: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 10: Chloride	101.9 Millimoles per liter Standard Deviation 2.02	—	—
Period 3: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 4: Phosphate	1.276 Millimoles per liter Standard Deviation 0.1304	—	—
Period 3: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 7: Phosphate	1.268 Millimoles per liter Standard Deviation 0.1802	—	—
Period 3: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 10: Phosphate	1.229 Millimoles per liter Standard Deviation 0.1213	—	—
Period 3: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 4: Potassium	4.19 Millimoles per liter Standard Deviation 0.150	—	—
Period 3: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 7: Potassium	4.19 Millimoles per liter Standard Deviation 0.217	—	—
Period 3: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 10: Potassium	4.29 Millimoles per liter Standard Deviation 0.275	—	—
Period 3: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 4: Sodium	137.6 Millimoles per liter Standard Deviation 2.06	—	—
Period 3: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 7: Sodium	139.5 Millimoles per liter Standard Deviation 2.56	—	—
Period 3: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 4: Blood urea nitrogen	5.119 Millimoles per liter Standard Deviation 0.8548	—	—
Period 3: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen Day 7: Blood urea nitrogen	4.887 Millimoles per liter Standard Deviation 0.6388	—	—

SECONDARY outcome

Timeframe: Day 9

Population: Safety Population.

Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Creatine kinase	101.3 International units per liter Standard Deviation 57.10	—	—
Period 1: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Lactate dehydrogenase	107.4 International units per liter Standard Deviation 14.33	—	—
Period 1: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase ALT	21.0 International units per liter Standard Deviation 10.71	—	—
Period 1: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase ALP	57.4 International units per liter Standard Deviation 8.74	—	—
Period 1: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase AST	16.6 International units per liter Standard Deviation 3.86	—	—
Period 1: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Gamma-glutamyl transferase	21.1 International units per liter Standard Deviation 9.24	—	—

SECONDARY outcome

Timeframe: Day 7

Population: Safety Population.

Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Creatine kinase	123.9 International units per liter Standard Deviation 112.28	—	—
Period 2: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Lactate dehydrogenase	116.5 International units per liter Standard Deviation 15.10	—	—
Period 2: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase ALT	20.4 International units per liter Standard Deviation 9.88	—	—
Period 2: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase ALP	59.3 International units per liter Standard Deviation 9.19	—	—
Period 2: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase AST	16.8 International units per liter Standard Deviation 3.80	—	—
Period 2: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Gamma-glutamyl transferase	20.3 International units per liter Standard Deviation 8.44	—	—

SECONDARY outcome

Timeframe: Days 4, 7 and 10

Population: Safety Population.

Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Day 4: Gamma-glutamyl transferase	19.5 International units per liter Standard Deviation 8.38	—	—
Period 3: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Day 4: Creatine kinase	110.3 International units per liter Standard Deviation 67.02	—	—
Period 3: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Day 7: Creatine kinase	105.3 International units per liter Standard Deviation 63.83	—	—
Period 3: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Day 10: Creatine kinase	100.3 International units per liter Standard Deviation 50.51	—	—
Period 3: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Day 4: Lactate dehydrogenase	122.4 International units per liter Standard Deviation 16.26	—	—
Period 3: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Day 7: Lactate dehydrogenase	115.6 International units per liter Standard Deviation 15.47	—	—
Period 3: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Day 10: Lactate dehydrogenase	116.6 International units per liter Standard Deviation 18.79	—	—
Period 3: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Day 4: ALT	21.4 International units per liter Standard Deviation 11.98	—	—
Period 3: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Day 7: ALT	21.1 International units per liter Standard Deviation 12.00	—	—
Period 3: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Day 10: ALT	22.3 International units per liter Standard Deviation 12.93	—	—
Period 3: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Day 4: ALP	57.8 International units per liter Standard Deviation 9.34	—	—
Period 3: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Day 7: ALP	58.8 International units per liter Standard Deviation 9.63	—	—
Period 3: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Day 10: ALP	60.1 International units per liter Standard Deviation 9.07	—	—
Period 3: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Day 4: AST	17.7 International units per liter Standard Deviation 5.12	—	—
Period 3: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Day 7: AST	16.3 International units per liter Standard Deviation 4.78	—	—
Period 3: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Day 10: AST	17.1 International units per liter Standard Deviation 4.55	—	—
Period 3: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Day 7: Gamma-glutamyl transferase	20.1 International units per liter Standard Deviation 8.35	—	—
Period 3: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase Day 10: Gamma-glutamyl transferase	20.8 International units per liter Standard Deviation 9.13	—	—

SECONDARY outcome

Timeframe: Day 9

Population: Safety Population.

Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Absolute Values for Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Urate	321.9 Micromoles per liter Standard Deviation 64.43	—	—
Period 1: Absolute Values for Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Creatinine	90.28 Micromoles per liter Standard Deviation 11.281	—	—
Period 1: Absolute Values for Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Bilirubin	9.14 Micromoles per liter Standard Deviation 2.423	—	—
Period 1: Absolute Values for Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Direct bilirubin	1.87 Micromoles per liter Standard Deviation 0.551	—	—

SECONDARY outcome

Timeframe: Day 7

Population: Safety Population.

Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Absolute Values for Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Urate	314.8 Micromoles per liter Standard Deviation 69.34	—	—
Period 2: Absolute Values for Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Creatinine	86.92 Micromoles per liter Standard Deviation 11.567	—	—
Period 2: Absolute Values for Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Bilirubin	9.41 Micromoles per liter Standard Deviation 3.014	—	—
Period 2: Absolute Values for Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Direct bilirubin	1.93 Micromoles per liter Standard Deviation 0.704	—	—

SECONDARY outcome

Timeframe: Days 4, 7 and 10

Population: Safety Population.

Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Absolute Values for Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Day 4: Urate	314.8 Micromoles per liter Standard Deviation 65.44	—	—
Period 3: Absolute Values for Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Day 7: Urate	299.3 Micromoles per liter Standard Deviation 62.85	—	—
Period 3: Absolute Values for Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Day 10: Urate	313.4 Micromoles per liter Standard Deviation 60.33	—	—
Period 3: Absolute Values for Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Day 4: Creatinine	94.82 Micromoles per liter Standard Deviation 13.650	—	—
Period 3: Absolute Values for Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Day 7: Creatinine	96.81 Micromoles per liter Standard Deviation 12.861	—	—
Period 3: Absolute Values for Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Day 10: Creatinine	88.91 Micromoles per liter Standard Deviation 12.545	—	—
Period 3: Absolute Values for Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Day 4: Bilirubin	11.64 Micromoles per liter Standard Deviation 4.856	—	—
Period 3: Absolute Values for Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Day 7: Bilirubin	9.19 Micromoles per liter Standard Deviation 2.511	—	—
Period 3: Absolute Values for Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Day 10: Bilirubin	10.83 Micromoles per liter Standard Deviation 3.796	—	—
Period 3: Absolute Values for Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Day 4: Direct bilirubin	2.26 Micromoles per liter Standard Deviation 0.995	—	—
Period 3: Absolute Values for Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Day 7: Direct bilirubin	1.74 Micromoles per liter Standard Deviation 0.617	—	—
Period 3: Absolute Values for Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin Day 10: Direct bilirubin	2.15 Micromoles per liter Standard Deviation 0.784	—	—

SECONDARY outcome

Timeframe: Day 9

Population: Safety Population.

Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Absolute Values for Chemistry Parameters: Albumin, Globulin, Protein Albumin	44.1 Grams per liter Standard Deviation 3.32	—	—
Period 1: Absolute Values for Chemistry Parameters: Albumin, Globulin, Protein Globulin	27.9 Grams per liter Standard Deviation 3.59	—	—
Period 1: Absolute Values for Chemistry Parameters: Albumin, Globulin, Protein Protein	71.9 Grams per liter Standard Deviation 4.63	—	—

SECONDARY outcome

Timeframe: Day 7

Population: Safety Population.

Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Absolute Values for Chemistry Parameters: Albumin, Globulin, Protein Albumin	44.9 Grams per liter Standard Deviation 3.13	—	—
Period 2: Absolute Values for Chemistry Parameters: Albumin, Globulin, Protein Globulin	26.8 Grams per liter Standard Deviation 3.78	—	—
Period 2: Absolute Values for Chemistry Parameters: Albumin, Globulin, Protein Protein	71.8 Grams per liter Standard Deviation 4.73	—	—

SECONDARY outcome

Timeframe: Days 4, 7 and 10

Population: Safety Population.

Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Absolute Values for Chemistry Parameters: Albumin, Globulin, Protein Day 4: Albumin	45.9 Grams per liter Standard Deviation 3.12	—	—
Period 3: Absolute Values for Chemistry Parameters: Albumin, Globulin, Protein Day 7: Albumin	45.1 Grams per liter Standard Deviation 2.83	—	—
Period 3: Absolute Values for Chemistry Parameters: Albumin, Globulin, Protein Day 10: Albumin	45.3 Grams per liter Standard Deviation 2.80	—	—
Period 3: Absolute Values for Chemistry Parameters: Albumin, Globulin, Protein Day 4: Globulin	25.9 Grams per liter Standard Deviation 3.52	—	—
Period 3: Absolute Values for Chemistry Parameters: Albumin, Globulin, Protein Day 7: Globulin	27.8 Grams per liter Standard Deviation 3.49	—	—
Period 3: Absolute Values for Chemistry Parameters: Albumin, Globulin, Protein Day 10: Globulin	27.3 Grams per liter Standard Deviation 3.34	—	—
Period 3: Absolute Values for Chemistry Parameters: Albumin, Globulin, Protein Day 4: Protein	71.8 Grams per liter Standard Deviation 3.89	—	—
Period 3: Absolute Values for Chemistry Parameters: Albumin, Globulin, Protein Day 7: Protein	72.9 Grams per liter Standard Deviation 4.28	—	—
Period 3: Absolute Values for Chemistry Parameters: Albumin, Globulin, Protein Day 10: Protein	72.6 Grams per liter Standard Deviation 4.11	—	—

SECONDARY outcome

Timeframe: Day 9

Population: Safety Population.

Blood samples were collected to analyze the chemistry parameters: amylase and lipase.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Absolute Values for Chemistry Parameters: Amylase, Lipase Amylase	59.6 Units per liter Standard Deviation 21.96	—	—
Period 1: Absolute Values for Chemistry Parameters: Amylase, Lipase Lipase	22.4 Units per liter Standard Deviation 8.57	—	—

SECONDARY outcome

Timeframe: Day 7

Population: Safety Population.

Blood samples were collected to analyze the chemistry parameters: amylase and lipase.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Absolute Values for Chemistry Parameters: Amylase, Lipase Amylase	56.8 Units per liter Standard Deviation 19.06	—	—
Period 2: Absolute Values for Chemistry Parameters: Amylase, Lipase Lipase	21.7 Units per liter Standard Deviation 7.34	—	—

SECONDARY outcome

Timeframe: Days 4, 7 and 10

Population: Safety Population.

Blood samples were collected to analyze the chemistry parameters: amylase and lipase.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Absolute Values for Chemistry Parameters: Amylase, Lipase Day 4: Amylase	55.3 Units per liter Standard Deviation 18.81	—	—
Period 3: Absolute Values for Chemistry Parameters: Amylase, Lipase Day 7: Amylase	56.9 Units per liter Standard Deviation 21.03	—	—
Period 3: Absolute Values for Chemistry Parameters: Amylase, Lipase Day 10: Amylase	55.9 Units per liter Standard Deviation 20.57	—	—
Period 3: Absolute Values for Chemistry Parameters: Amylase, Lipase Day 4: Lipase	26.4 Units per liter Standard Deviation 11.10	—	—
Period 3: Absolute Values for Chemistry Parameters: Amylase, Lipase Day 7: Lipase	20.9 Units per liter Standard Deviation 9.12	—	—
Period 3: Absolute Values for Chemistry Parameters: Amylase, Lipase Day 10: Lipase	21.8 Units per liter Standard Deviation 9.25	—	—

SECONDARY outcome

Timeframe: Day 9

Population: Safety Population.

Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Absolute Values for Urinalysis Parameter: Specific Gravity	1.0181 Ratio Standard Deviation 0.00662	—	—

SECONDARY outcome

Timeframe: Day 7

Population: Safety Population.

Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Absolute Values for Urinalysis Parameter: Specific Gravity	1.0176 Ratio Standard Deviation 0.00552	—	—

SECONDARY outcome

Timeframe: Days 4, 7 and 10

Population: Safety Population.

Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Absolute Values for Urinalysis Parameter: Specific Gravity Day 4	1.0179 Ratio Standard Deviation 0.00712	—	—
Period 3: Absolute Values for Urinalysis Parameter: Specific Gravity Day 7	1.0169 Ratio Standard Deviation 0.00640	—	—
Period 3: Absolute Values for Urinalysis Parameter: Specific Gravity Day 10	1.0160 Ratio Standard Deviation 0.00747	—	—

SECONDARY outcome

Timeframe: Day 9

Population: Safety Population.

Urine samples were collected to analyze the urinalysis parameter: urobilinogen.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Absolute Values for Urinalysis Parameter: Urobilinogen	3.3860 Micromoles per liter Standard Deviation 0.00000	—	—

SECONDARY outcome

Timeframe: Day 7

Population: Safety Population.

Urine samples were collected to analyze the urinalysis parameter: urobilinogen.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Absolute Values for Urinalysis Parameter: Urobilinogen	3.3860 Micromoles per liter Standard Deviation 0.00000	—	—

SECONDARY outcome

Timeframe: Days 4, 7 and 10

Population: Safety Population.

Urine samples were collected to analyze the urinalysis parameter: urobilinogen.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Absolute Values for Urinalysis Parameter: Urobilinogen Day 4	3.3860 Micromoles per liter Standard Deviation 0.00000	—	—
Period 3: Absolute Values for Urinalysis Parameter: Urobilinogen Day 7	3.3860 Micromoles per liter Standard Deviation 0.00000	—	—
Period 3: Absolute Values for Urinalysis Parameter: Urobilinogen Day 10	3.3860 Micromoles per liter Standard Deviation 0.00000	—	—

SECONDARY outcome

Timeframe: Day 9

Population: Safety Population.

Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0).

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Absolute Values for Urinalysis Parameter: pH	5.88 pH Standard Deviation 0.465	—	—

SECONDARY outcome

Timeframe: Day 7

Population: Safety Population.

Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0).

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Absolute Values for Urinalysis Parameter: pH	6.00 pH Standard Deviation 0.548	—	—

SECONDARY outcome

Timeframe: Days 4, 7 and 10

Population: Safety Population.

Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0).

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Absolute Values for Urinalysis Parameter: pH Day 4	6.03 pH Standard Deviation 0.591	—	—
Period 3: Absolute Values for Urinalysis Parameter: pH Day 7	5.88 pH Standard Deviation 0.387	—	—
Period 3: Absolute Values for Urinalysis Parameter: pH Day 10	6.16 pH Standard Deviation 0.473	—	—

SECONDARY outcome

Timeframe: Day 1: 2 hours, 4 hours; Day 5: Pre-dose, 2 hours and 4 hours

Population: Safety Population.

Twelve-lead ECG were obtained to measure PR Interval, QRS Duration, QT Interval, QTcF Interval and QTcB Interval. Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcF Interval: Day 5, 2 hours	388.6 Milliseconds Standard Deviation 14.47	—	—
Period 1: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcF Interval: Day 5, 4 hours	392.7 Milliseconds Standard Deviation 14.11	—	—
Period 1: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB PR Interval: Day 1, 2 hours	159.1 Milliseconds Standard Deviation 14.42	—	—
Period 1: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB PR Interval: Day 1, 4 hours	161.3 Milliseconds Standard Deviation 16.51	—	—
Period 1: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB PR Interval: Day 5, Pre-dose	164.3 Milliseconds Standard Deviation 14.87	—	—
Period 1: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB PR Interval: Day 5, 2 hours	160.9 Milliseconds Standard Deviation 11.34	—	—
Period 1: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB PR Interval: Day 5, 4 hours	161.5 Milliseconds Standard Deviation 12.66	—	—
Period 1: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QRS Duration: Day 1, 2 hours	95.2 Milliseconds Standard Deviation 9.59	—	—
Period 1: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QRS Duration: Day 1, 4 hours	94.7 Milliseconds Standard Deviation 10.90	—	—
Period 1: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QRS Duration: Day 5, Pre-dose	92.6 Milliseconds Standard Deviation 8.39	—	—
Period 1: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QRS Duration: Day 5, 2 hours	94.2 Milliseconds Standard Deviation 10.78	—	—
Period 1: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QRS Duration: Day 5, 4 hours	94.0 Milliseconds Standard Deviation 9.26	—	—
Period 1: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QT Interval: Day 1, 2 hours	386.4 Milliseconds Standard Deviation 16.06	—	—
Period 1: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QT Interval: Day 1, 4 hours	401.8 Milliseconds Standard Deviation 19.94	—	—
Period 1: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QT Interval: Day 5, Pre-dose	385.1 Milliseconds Standard Deviation 13.96	—	—
Period 1: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QT Interval: Day 5, 2 hours	375.6 Milliseconds Standard Deviation 11.46	—	—
Period 1: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QT Interval: Day 5, 4 hours	393.1 Milliseconds Standard Deviation 18.80	—	—
Period 1: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcF Interval: Day 1, 2 hours	391.6 Milliseconds Standard Deviation 11.37	—	—
Period 1: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcF Interval: Day 1, 4 hours	395.0 Milliseconds Standard Deviation 12.90	—	—
Period 1: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcF Interval: Day 5, Pre-dose	389.5 Milliseconds Standard Deviation 10.92	—	—
Period 1: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcB Interval: Day 1, 2 hours	393.1 Milliseconds Standard Deviation 15.31	—	—
Period 1: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcB Interval: Day 1, 4 hours	390.2 Milliseconds Standard Deviation 16.01	—	—
Period 1: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcB Interval: Day 5, Pre-dose	390.9 Milliseconds Standard Deviation 14.91	—	—
Period 1: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcB Interval: Day 5, 2 hours	394.2 Milliseconds Standard Deviation 21.59	—	—
Period 1: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcB Interval: Day 5, 4 hours	391.7 Milliseconds Standard Deviation 19.71	—	—

SECONDARY outcome

Timeframe: Day 1: 2 hours, 4 hours; Day 5: Pre-dose, 2 hours and 4 hours

Population: Safety Population.

Twelve-lead ECG were obtained to measure PR Interval, QRS Duration, QT Interval, QTcF Interval and QTcB Interval. Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB PR Interval: Day 1, 2 hours	165.1 Milliseconds Standard Deviation 15.46	—	—
Period 2: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB PR Interval: Day 1, 4 hours	165.4 Milliseconds Standard Deviation 14.32	—	—
Period 2: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB PR Interval: Day 5, Pre-dose	166.3 Milliseconds Standard Deviation 16.89	—	—
Period 2: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB PR Interval: Day 5, 2 hours	165.0 Milliseconds Standard Deviation 19.90	—	—
Period 2: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB PR Interval: Day 5, 4 hours	162.0 Milliseconds Standard Deviation 13.64	—	—
Period 2: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QRS Duration: Day 1, 2 hours	94.1 Milliseconds Standard Deviation 9.66	—	—
Period 2: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QRS Duration: Day 1, 4 hours	92.9 Milliseconds Standard Deviation 9.20	—	—
Period 2: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QRS Duration: Day 5, Pre-dose	94.3 Milliseconds Standard Deviation 10.12	—	—
Period 2: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QRS Duration: Day 5, 2 hours	93.9 Milliseconds Standard Deviation 9.00	—	—
Period 2: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QRS Duration: Day 5, 4 hours	94.7 Milliseconds Standard Deviation 8.51	—	—
Period 2: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QT Interval: Day 1, 2 hours	381.8 Milliseconds Standard Deviation 14.37	—	—
Period 2: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QT Interval: Day 1, 4 hours	394.4 Milliseconds Standard Deviation 19.18	—	—
Period 2: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QT Interval: Day 5, Pre-dose	392.6 Milliseconds Standard Deviation 23.20	—	—
Period 2: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QT Interval: Day 5, 2 hours	382.6 Milliseconds Standard Deviation 17.13	—	—
Period 2: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QT Interval: Day 5, 4 hours	396.0 Milliseconds Standard Deviation 21.45	—	—
Period 2: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcF Interval: Day 1, 2 hours	390.0 Milliseconds Standard Deviation 13.74	—	—
Period 2: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcF Interval: Day 1, 4 hours	394.4 Milliseconds Standard Deviation 12.38	—	—
Period 2: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcF Interval: Day 5, Pre-dose	397.9 Milliseconds Standard Deviation 14.64	—	—
Period 2: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcF Interval: Day 5, 2 hours	395.0 Milliseconds Standard Deviation 14.70	—	—
Period 2: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcF Interval: Day 5, 4 hours	401.5 Milliseconds Standard Deviation 12.66	—	—
Period 2: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcB Interval: Day 1, 2 hours	393.3 Milliseconds Standard Deviation 18.57	—	—
Period 2: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcB Interval: Day 1, 4 hours	393.4 Milliseconds Standard Deviation 18.53	—	—
Period 2: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcB Interval: Day 5, Pre-dose	399.2 Milliseconds Standard Deviation 16.61	—	—
Period 2: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcB Interval: Day 5, 2 hours	400.7 Milliseconds Standard Deviation 20.02	—	—
Period 2: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcB Interval: Day 5, 4 hours	403.2 Milliseconds Standard Deviation 13.41	—	—

SECONDARY outcome

Timeframe: Day 1: 2 hours, 4 hours; Days 4, 5 and 7: Pre-dose, 2 hours and 4 hours; Day 10

Population: Safety Population.

Twelve-lead ECG were obtained to measure PR Interval, QRS Duration, QT Interval, QTcF Interval and QTcB Interval. Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB PR Interval: Day 5, 2 hours	162.8 Milliseconds Standard Deviation 12.71	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB PR Interval: Day 1, 2 hours	167.9 Milliseconds Standard Deviation 13.86	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB PR Interval: Day 1, 4 hours	164.1 Milliseconds Standard Deviation 15.12	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB PR Interval: Day 4, Pre-dose	165.6 Milliseconds Standard Deviation 16.02	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB PR Interval: Day 4, 2 hours	166.9 Milliseconds Standard Deviation 15.67	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB PR Interval: Day 4, 4 hours	163.1 Milliseconds Standard Deviation 15.13	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB PR Interval: Day 5, Pre-dose	164.6 Milliseconds Standard Deviation 18.30	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB PR Interval: Day 5, 4 hours	163.3 Milliseconds Standard Deviation 14.96	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB PR Interval: Day 7, Pre-dose	169.6 Milliseconds Standard Deviation 17.47	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB PR Interval: Day 7, 2 hours	165.0 Milliseconds Standard Deviation 15.69	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB PR Interval: Day 7, 4 hours	165.6 Milliseconds Standard Deviation 15.00	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB PR Interval: Day 10	168.3 Milliseconds Standard Deviation 17.14	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QRS Duration: Day 1, 2 hours	95.9 Milliseconds Standard Deviation 10.49	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QRS Duration: Day 1, 4 hours	92.8 Milliseconds Standard Deviation 8.76	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QRS Duration: Day 4, Pre-dose	96.8 Milliseconds Standard Deviation 9.41	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QRS Duration: Day 4, 2 hours	93.5 Milliseconds Standard Deviation 8.21	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QRS Duration: Day 4, 4 hours	95.3 Milliseconds Standard Deviation 8.79	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QRS Duration: Day 5, Pre-dose	96.6 Milliseconds Standard Deviation 9.77	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QRS Duration: Day 5, 2 hours	96.1 Milliseconds Standard Deviation 11.66	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QRS Duration: Day 5, 4 hours	94.3 Milliseconds Standard Deviation 9.56	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QRS Duration: Day 7, Pre-dose	95.4 Milliseconds Standard Deviation 9.44	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QRS Duration: Day 7, 2 hours	95.1 Milliseconds Standard Deviation 9.52	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QRS Duration: Day 7, 4 hours	94.4 Milliseconds Standard Deviation 9.30	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QRS Duration: Day 10	96.5 Milliseconds Standard Deviation 9.14	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QT Interval: Day 1, 2 hours	380.0 Milliseconds Standard Deviation 12.90	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QT Interval: Day 1, 4 hours	392.3 Milliseconds Standard Deviation 16.39	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QT Interval: Day 4, Pre-dose	389.2 Milliseconds Standard Deviation 18.65	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QT Interval: Day 4, 2 hours	376.6 Milliseconds Standard Deviation 18.49	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QT Interval: Day 4, 4 hours	395.3 Milliseconds Standard Deviation 17.89	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QT Interval: Day 5, Pre-dose	386.4 Milliseconds Standard Deviation 18.49	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QT Interval: Day 5, 2 hours	380.9 Milliseconds Standard Deviation 13.91	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QT Interval: Day 5, 4 hours	391.8 Milliseconds Standard Deviation 20.53	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QT Interval: Day 7, Pre-dose	391.0 Milliseconds Standard Deviation 21.99	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QT Interval: Day 7, 2 hours	382.3 Milliseconds Standard Deviation 13.85	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QT Interval: Day 7, 4 hours	395.8 Milliseconds Standard Deviation 20.94	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QT Interval: Day 10	392.9 Milliseconds Standard Deviation 14.54	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcF Interval: Day 1, 2 hours	392.7 Milliseconds Standard Deviation 11.45	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcF Interval: Day 1, 4 hours	399.7 Milliseconds Standard Deviation 10.37	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcF Interval: Day 4, Pre-dose	395.8 Milliseconds Standard Deviation 13.94	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcF Interval: Day 4, 2 hours	390.6 Milliseconds Standard Deviation 12.33	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcF Interval: Day 4, 4 hours	401.2 Milliseconds Standard Deviation 13.55	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcF Interval: Day 5, Pre-dose	399.2 Milliseconds Standard Deviation 14.92	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcF Interval: Day 5, 2 hours	394.3 Milliseconds Standard Deviation 12.83	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcF Interval: Day 5, 4 hours	401.7 Milliseconds Standard Deviation 11.91	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcF Interval: Day 7, Pre-dose	395.1 Milliseconds Standard Deviation 12.91	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcF Interval: Day 7, 2 hours	393.7 Milliseconds Standard Deviation 12.69	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcF Interval: Day 7, 4 hours	396.8 Milliseconds Standard Deviation 13.47	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcF Interval: Day 10	394.8 Milliseconds Standard Deviation 13.08	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcB Interval: Day 1, 2 hours	398.4 Milliseconds Standard Deviation 15.81	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcB Interval: Day 1, 4 hours	402.0 Milliseconds Standard Deviation 15.46	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcB Interval: Day 4, Pre-dose	398.4 Milliseconds Standard Deviation 17.82	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcB Interval: Day 4, 2 hours	394.0 Milliseconds Standard Deviation 21.41	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcB Interval: Day 4, 4 hours	403.1 Milliseconds Standard Deviation 17.67	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcB Interval: Day 5, Pre-dose	405.1 Milliseconds Standard Deviation 23.00	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcB Interval: Day 5, 2 hours	400.1 Milliseconds Standard Deviation 18.05	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcB Interval: Day 5, 4 hours	405.9 Milliseconds Standard Deviation 16.27	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcB Interval: Day 7, Pre-dose	396.6 Milliseconds Standard Deviation 17.50	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcB Interval: Day 7, 2 hours	398.9 Milliseconds Standard Deviation 21.21	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcB Interval: Day 7, 4 hours	396.0 Milliseconds Standard Deviation 18.10	—	—
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB QTcB Interval: Day 10	394.8 Milliseconds Standard Deviation 18.39	—	—

SECONDARY outcome

Timeframe: Days 2, 3, 4 and 5

Population: Safety Population.

SBP and DBP were measured in the semi-recumbent position with a completely automated device.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Absolute Values for SBP and DBP SBP: Day 2	118.8 Millimeters of mercury Standard Deviation 8.57	—	—
Period 1: Absolute Values for SBP and DBP SBP: Day 3	114.9 Millimeters of mercury Standard Deviation 8.09	—	—
Period 1: Absolute Values for SBP and DBP SBP: Day 4	119.0 Millimeters of mercury Standard Deviation 9.81	—	—
Period 1: Absolute Values for SBP and DBP SBP: Day 5	109.1 Millimeters of mercury Standard Deviation 7.16	—	—
Period 1: Absolute Values for SBP and DBP DBP: Day 2	76.1 Millimeters of mercury Standard Deviation 6.53	—	—
Period 1: Absolute Values for SBP and DBP DBP: Day 3	72.7 Millimeters of mercury Standard Deviation 8.32	—	—
Period 1: Absolute Values for SBP and DBP DBP: Day 4	74.1 Millimeters of mercury Standard Deviation 8.58	—	—
Period 1: Absolute Values for SBP and DBP DBP: Day 5	69.2 Millimeters of mercury Standard Deviation 9.77	—	—

SECONDARY outcome

Timeframe: Days 2, 3, 4, 5, 6 and 7

Population: Safety Population.

SBP and DBP were measured in the semi-recumbent position with a completely automated device.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Absolute Values for SBP and DBP SBP: Day 2	115.8 Millimeters of mercury Standard Deviation 7.15	—	—
Period 2: Absolute Values for SBP and DBP SBP: Day 3	115.3 Millimeters of mercury Standard Deviation 7.57	—	—
Period 2: Absolute Values for SBP and DBP SBP: Day 4	117.1 Millimeters of mercury Standard Deviation 8.74	—	—
Period 2: Absolute Values for SBP and DBP SBP: Day 5	113.6 Millimeters of mercury Standard Deviation 7.35	—	—
Period 2: Absolute Values for SBP and DBP SBP: Day 6	113.9 Millimeters of mercury Standard Deviation 8.29	—	—
Period 2: Absolute Values for SBP and DBP SBP: Day 7	114.6 Millimeters of mercury Standard Deviation 5.73	—	—
Period 2: Absolute Values for SBP and DBP DBP: Day 2	69.6 Millimeters of mercury Standard Deviation 8.50	—	—
Period 2: Absolute Values for SBP and DBP DBP: Day 3	71.1 Millimeters of mercury Standard Deviation 7.65	—	—
Period 2: Absolute Values for SBP and DBP DBP: Day 4	69.6 Millimeters of mercury Standard Deviation 5.24	—	—
Period 2: Absolute Values for SBP and DBP DBP: Day 5	68.8 Millimeters of mercury Standard Deviation 6.49	—	—
Period 2: Absolute Values for SBP and DBP DBP: Day 6	70.3 Millimeters of mercury Standard Deviation 7.02	—	—
Period 2: Absolute Values for SBP and DBP DBP: Day 7	70.4 Millimeters of mercury Standard Deviation 6.65	—	—

SECONDARY outcome

Timeframe: Days 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11

Population: Safety Population.

SBP and DBP were measured in the semi-recumbent position with a completely automated device.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Absolute Values for SBP and DBP SBP: Day 2	115.8 Millimeters of mercury Standard Deviation 8.12	—	—
Period 3: Absolute Values for SBP and DBP SBP: Day 3	112.5 Millimeters of mercury Standard Deviation 5.81	—	—
Period 3: Absolute Values for SBP and DBP SBP: Day 4	112.6 Millimeters of mercury Standard Deviation 6.11	—	—
Period 3: Absolute Values for SBP and DBP SBP: Day 5	119.4 Millimeters of mercury Standard Deviation 19.70	—	—
Period 3: Absolute Values for SBP and DBP SBP: Day 6	114.4 Millimeters of mercury Standard Deviation 7.45	—	—
Period 3: Absolute Values for SBP and DBP SBP: Day 7	113.8 Millimeters of mercury Standard Deviation 8.13	—	—
Period 3: Absolute Values for SBP and DBP SBP: Day 8	113.9 Millimeters of mercury Standard Deviation 6.72	—	—
Period 3: Absolute Values for SBP and DBP SBP: Day 9	113.6 Millimeters of mercury Standard Deviation 7.67	—	—
Period 3: Absolute Values for SBP and DBP SBP: Day 10	111.6 Millimeters of mercury Standard Deviation 6.38	—	—
Period 3: Absolute Values for SBP and DBP SBP: Day 11	112.4 Millimeters of mercury Standard Deviation 7.69	—	—
Period 3: Absolute Values for SBP and DBP DBP: Day 2	69.0 Millimeters of mercury Standard Deviation 6.46	—	—
Period 3: Absolute Values for SBP and DBP DBP: Day 3	67.7 Millimeters of mercury Standard Deviation 6.52	—	—
Period 3: Absolute Values for SBP and DBP DBP: Day 4	68.9 Millimeters of mercury Standard Deviation 6.33	—	—
Period 3: Absolute Values for SBP and DBP DBP: Day 5	74.4 Millimeters of mercury Standard Deviation 21.90	—	—
Period 3: Absolute Values for SBP and DBP DBP: Day 6	69.2 Millimeters of mercury Standard Deviation 8.27	—	—
Period 3: Absolute Values for SBP and DBP DBP: Day 7	70.6 Millimeters of mercury Standard Deviation 5.78	—	—
Period 3: Absolute Values for SBP and DBP DBP: Day 8	69.5 Millimeters of mercury Standard Deviation 9.34	—	—
Period 3: Absolute Values for SBP and DBP DBP: Day 9	69.8 Millimeters of mercury Standard Deviation 5.98	—	—
Period 3: Absolute Values for SBP and DBP DBP: Day 10	70.0 Millimeters of mercury Standard Deviation 5.14	—	—
Period 3: Absolute Values for SBP and DBP DBP: Day 11	67.7 Millimeters of mercury Standard Deviation 4.32	—	—

SECONDARY outcome

Timeframe: Days 2, 3, 4 and 5

Population: Safety Population.

Pulse rate was measured in the semi-recumbent position with a completely automated device.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Absolute Values for Pulse Rate Day 2	67.8 Beats per minute Standard Deviation 8.47	—	—
Period 1: Absolute Values for Pulse Rate Day 3	66.8 Beats per minute Standard Deviation 6.68	—	—
Period 1: Absolute Values for Pulse Rate Day 4	70.1 Beats per minute Standard Deviation 10.57	—	—
Period 1: Absolute Values for Pulse Rate Day 5	66.4 Beats per minute Standard Deviation 8.21	—	—

SECONDARY outcome

Timeframe: Days 2, 3, 4, 5, 6 and 7

Population: Safety Population.

Pulse rate was measured in the semi-recumbent position with a completely automated device.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Absolute Values for Pulse Rate Day 2	68.3 Beats per minute Standard Deviation 9.75	—	—
Period 2: Absolute Values for Pulse Rate Day 3	69.7 Beats per minute Standard Deviation 8.65	—	—
Period 2: Absolute Values for Pulse Rate Day 4	69.1 Beats per minute Standard Deviation 8.21	—	—
Period 2: Absolute Values for Pulse Rate Day 5	68.5 Beats per minute Standard Deviation 11.14	—	—
Period 2: Absolute Values for Pulse Rate Day 6	68.1 Beats per minute Standard Deviation 8.88	—	—
Period 2: Absolute Values for Pulse Rate Day 7	67.0 Beats per minute Standard Deviation 8.95	—	—

SECONDARY outcome

Timeframe: Days 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11

Population: Safety Population.

Pulse rate was measured in the semi-recumbent position with a completely automated device.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Absolute Values for Pulse Rate Day 9	65.9 Beats per minute Standard Deviation 10.12	—	—
Period 3: Absolute Values for Pulse Rate Day 2	68.4 Beats per minute Standard Deviation 9.79	—	—
Period 3: Absolute Values for Pulse Rate Day 3	68.9 Beats per minute Standard Deviation 8.63	—	—
Period 3: Absolute Values for Pulse Rate Day 4	66.9 Beats per minute Standard Deviation 9.26	—	—
Period 3: Absolute Values for Pulse Rate Day 5	69.8 Beats per minute Standard Deviation 10.57	—	—
Period 3: Absolute Values for Pulse Rate Day 6	67.9 Beats per minute Standard Deviation 10.12	—	—
Period 3: Absolute Values for Pulse Rate Day 7	64.6 Beats per minute Standard Deviation 8.02	—	—
Period 3: Absolute Values for Pulse Rate Day 8	69.0 Beats per minute Standard Deviation 12.02	—	—
Period 3: Absolute Values for Pulse Rate Day 10	63.8 Beats per minute Standard Deviation 8.53	—	—
Period 3: Absolute Values for Pulse Rate Day 11	68.4 Beats per minute Standard Deviation 12.27	—	—

SECONDARY outcome

Timeframe: Days 2, 3, 4 and 5

Population: Safety Population.

Respiratory rate was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Absolute Values for Respiratory Rate Day 2	13.5 Breaths per minute Standard Deviation 1.37	—	—
Period 1: Absolute Values for Respiratory Rate Day 3	14.6 Breaths per minute Standard Deviation 2.16	—	—
Period 1: Absolute Values for Respiratory Rate Day 4	12.9 Breaths per minute Standard Deviation 1.78	—	—
Period 1: Absolute Values for Respiratory Rate Day 5	13.6 Breaths per minute Standard Deviation 2.22	—	—

SECONDARY outcome

Timeframe: Days 2, 3, 4, 5, 6 and 7

Population: Safety Population. Only those participants with data available at the indicated time points were analyzed (represented by n= X in the category titles).

Respiratory rate was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Absolute Values for Respiratory Rate Day 2, n=16	13.6 Breaths per minute Standard Deviation 0.81	—	—
Period 2: Absolute Values for Respiratory Rate Day 3, n=16	14.5 Breaths per minute Standard Deviation 2.00	—	—
Period 2: Absolute Values for Respiratory Rate Day 4, n=16	13.5 Breaths per minute Standard Deviation 1.15	—	—
Period 2: Absolute Values for Respiratory Rate Day 5, n=15	15.3 Breaths per minute Standard Deviation 2.09	—	—
Period 2: Absolute Values for Respiratory Rate Day 6, n=16	13.8 Breaths per minute Standard Deviation 2.52	—	—
Period 2: Absolute Values for Respiratory Rate Day 7, n=16	14.3 Breaths per minute Standard Deviation 2.18	—	—

SECONDARY outcome

Timeframe: Days 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11

Population: Safety Population.

Respiratory rate was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Absolute Values for Respiratory Rate Day 2	15.0 Breaths per minute Standard Deviation 2.42	—	—
Period 3: Absolute Values for Respiratory Rate Day 3	14.1 Breaths per minute Standard Deviation 1.54	—	—
Period 3: Absolute Values for Respiratory Rate Day 4	13.9 Breaths per minute Standard Deviation 2.96	—	—
Period 3: Absolute Values for Respiratory Rate Day 5	13.1 Breaths per minute Standard Deviation 1.45	—	—
Period 3: Absolute Values for Respiratory Rate Day 6	14.3 Breaths per minute Standard Deviation 2.05	—	—
Period 3: Absolute Values for Respiratory Rate Day 7	13.9 Breaths per minute Standard Deviation 1.86	—	—
Period 3: Absolute Values for Respiratory Rate Day 8	15.0 Breaths per minute Standard Deviation 1.03	—	—
Period 3: Absolute Values for Respiratory Rate Day 9	13.3 Breaths per minute Standard Deviation 3.00	—	—
Period 3: Absolute Values for Respiratory Rate Day 10	15.0 Breaths per minute Standard Deviation 1.79	—	—
Period 3: Absolute Values for Respiratory Rate Day 11	16.4 Breaths per minute Standard Deviation 1.31	—	—

SECONDARY outcome

Timeframe: Days 2, 3, 4 and 5

Population: Safety Population.

Body temperature was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Absolute Values for Body Temperature Day 2	36.36 Degrees Celsius Standard Deviation 0.303	—	—
Period 1: Absolute Values for Body Temperature Day 3	36.26 Degrees Celsius Standard Deviation 0.287	—	—
Period 1: Absolute Values for Body Temperature Day 4	36.21 Degrees Celsius Standard Deviation 0.361	—	—
Period 1: Absolute Values for Body Temperature Day 5	36.43 Degrees Celsius Standard Deviation 0.270	—	—

SECONDARY outcome

Timeframe: Days 2, 3, 4, 5, 6 and 7

Population: Safety Population.

Body temperature was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Absolute Values for Body Temperature Day 2	36.26 Degrees Celsius Standard Deviation 0.339	—	—
Period 2: Absolute Values for Body Temperature Day 3	36.15 Degrees Celsius Standard Deviation 0.361	—	—
Period 2: Absolute Values for Body Temperature Day 4	36.21 Degrees Celsius Standard Deviation 0.318	—	—
Period 2: Absolute Values for Body Temperature Day 5	36.35 Degrees Celsius Standard Deviation 0.306	—	—
Period 2: Absolute Values for Body Temperature Day 6	36.28 Degrees Celsius Standard Deviation 0.309	—	—
Period 2: Absolute Values for Body Temperature Day 7	36.28 Degrees Celsius Standard Deviation 0.394	—	—

SECONDARY outcome

Timeframe: Days 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11

Population: Safety Population.

Body temperature was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Absolute Values for Body Temperature Day 2	36.33 Degrees Celsius Standard Deviation 0.284	—	—
Period 3: Absolute Values for Body Temperature Day 3	36.22 Degrees Celsius Standard Deviation 0.369	—	—
Period 3: Absolute Values for Body Temperature Day 4	36.42 Degrees Celsius Standard Deviation 0.412	—	—
Period 3: Absolute Values for Body Temperature Day 5	36.40 Degrees Celsius Standard Deviation 0.405	—	—
Period 3: Absolute Values for Body Temperature Day 6	36.37 Degrees Celsius Standard Deviation 0.366	—	—
Period 3: Absolute Values for Body Temperature Day 7	36.46 Degrees Celsius Standard Deviation 0.371	—	—
Period 3: Absolute Values for Body Temperature Day 8	36.28 Degrees Celsius Standard Deviation 0.451	—	—
Period 3: Absolute Values for Body Temperature Day 9	36.30 Degrees Celsius Standard Deviation 0.337	—	—
Period 3: Absolute Values for Body Temperature Day 10	36.37 Degrees Celsius Standard Deviation 0.294	—	—
Period 3: Absolute Values for Body Temperature Day 11	36.53 Degrees Celsius Standard Deviation 0.307	—	—

SECONDARY outcome

Timeframe: Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

Population: Pharmacokinetic Parameter Population.

Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Time of Maximum Observed Concentration (Tmax) of GSK3640254 for GSK3640254 Arm	5.000 Hours Interval 3.5 to 8.0	—	—

SECONDARY outcome

Timeframe: Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

Population: Pharmacokinetic Parameter Population.

Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Tmax of GSK3640254 for Dolutegravir + GSK3640254 Arm	5.000 Hours Interval 3.5 to 8.0	—	—

SECONDARY outcome

Timeframe: Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

Population: Pharmacokinetic Parameter Population.

Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis. Data could not be determined due to limited sampling points after final dosing (during elimination phase). An accurate determination of GSK3640254 half-life would require sampling up to 3 times half-life (3 \* approximately 24 hours). However sampling in Period 2 was performed up to only 24 hours post-dose.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 2: Apparent Terminal Phase Half-life (T1/2) of GSK3640254 for GSK3640254 Arm	NA Hours Geometric Coefficient of Variation NA Data could not be determined due to limited sampling points after final dosing (during elimination phase). An accurate determination of GSK3640254 half-life would require sampling up to 3 times half-life (3 \* approximately 24 hours).	—	—

SECONDARY outcome

Timeframe: Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

Population: Pharmacokinetic Parameter Population.

Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: T1/2 of GSK3640254 for Dolutegravir + GSK3640254 Arm	23.417 Hours Geometric Coefficient of Variation 15.0	—	—

SECONDARY outcome

Timeframe: Day 5: Pre-dose, 1, 1.5, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

Population: Pharmacokinetic Parameter Population.

Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: Tmax of Dolutegravir for Dolutegravir Arm	3.000 Hours Interval 1.0 to 4.5	—	—

SECONDARY outcome

Timeframe: Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

Population: Pharmacokinetic Parameter Population.

Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: Tmax of Dolutegravir for Dolutegravir + GSK3640254 Arm	3.000 Hours Interval 1.0 to 4.5	—	—

SECONDARY outcome

Timeframe: Day 5: Pre-dose, 1, 1.5, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

Population: Pharmacokinetic Parameter Population.

Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 1: T1/2 of Dolutegravir for Dolutegravir Arm	14.492 Hours Geometric Coefficient of Variation 11.8	—	—

SECONDARY outcome

Timeframe: Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

Population: Pharmacokinetic Parameter Population.

Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Dolutegravir 50 mg n=16 Participants In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7	Dolutegravir 50 mg + GSK3640254 200 mg In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Period 3: T1/2 of Dolutegravir for Dolutegravir + GSK3640254 Arm	14.690 Hours Geometric Coefficient of Variation 12.1	—	—

Adverse Events

Dolutegravir 50 mg

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

GSK3640254 200 mg

Serious events: 0 serious events

Other events: 3 other events

Deaths: 0 deaths

Dolutegravir 50 mg + GSK3640254 200 mg

Serious events: 0 serious events

Other events: 2 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure	Dolutegravir 50 mg n=16 participants at risk In Period 1, participants received dolutegravir 50 mg, tablets, orally (treatment A) once daily on Days 1 through 5 followed by a wash-out period of 4 days. A wash out period was maintained between the last dose of study treatment A in Period 1 and initiation of study treatment B in Period 2.	GSK3640254 200 mg n=16 participants at risk In Period 2, participants received GSK3640254 200 mg, capsules, orally (treatment B) once daily on Days 1 through 7.	Dolutegravir 50 mg + GSK3640254 200 mg n=16 participants at risk In Period 3, participants co-administered dolutegravir 50 mg, tablets, orally, once daily along with GSK3640254 200 mg, capsules, orally (treatment C), once daily on Days 1 through 7. Participants were followed up for 4 days after last dose of study treatment.
Skin and subcutaneous tissue disorders Dermatitis	0.00% 0/16 • Non-SAEs and SAEs were collected from start of the study treatment up to Day 27 Safety Population consisted of all participants who received at least 1 dose of study medication.	0.00% 0/16 • Non-SAEs and SAEs were collected from start of the study treatment up to Day 27 Safety Population consisted of all participants who received at least 1 dose of study medication.	6.2% 1/16 • Non-SAEs and SAEs were collected from start of the study treatment up to Day 27 Safety Population consisted of all participants who received at least 1 dose of study medication.
Skin and subcutaneous tissue disorders Dermatitis contact	0.00% 0/16 • Non-SAEs and SAEs were collected from start of the study treatment up to Day 27 Safety Population consisted of all participants who received at least 1 dose of study medication.	0.00% 0/16 • Non-SAEs and SAEs were collected from start of the study treatment up to Day 27 Safety Population consisted of all participants who received at least 1 dose of study medication.	6.2% 1/16 • Non-SAEs and SAEs were collected from start of the study treatment up to Day 27 Safety Population consisted of all participants who received at least 1 dose of study medication.
Skin and subcutaneous tissue disorders Keratosis pilaris	0.00% 0/16 • Non-SAEs and SAEs were collected from start of the study treatment up to Day 27 Safety Population consisted of all participants who received at least 1 dose of study medication.	6.2% 1/16 • Non-SAEs and SAEs were collected from start of the study treatment up to Day 27 Safety Population consisted of all participants who received at least 1 dose of study medication.	0.00% 0/16 • Non-SAEs and SAEs were collected from start of the study treatment up to Day 27 Safety Population consisted of all participants who received at least 1 dose of study medication.
General disorders Medical device site dermatitis	0.00% 0/16 • Non-SAEs and SAEs were collected from start of the study treatment up to Day 27 Safety Population consisted of all participants who received at least 1 dose of study medication.	6.2% 1/16 • Non-SAEs and SAEs were collected from start of the study treatment up to Day 27 Safety Population consisted of all participants who received at least 1 dose of study medication.	6.2% 1/16 • Non-SAEs and SAEs were collected from start of the study treatment up to Day 27 Safety Population consisted of all participants who received at least 1 dose of study medication.
General disorders Fatigue	0.00% 0/16 • Non-SAEs and SAEs were collected from start of the study treatment up to Day 27 Safety Population consisted of all participants who received at least 1 dose of study medication.	0.00% 0/16 • Non-SAEs and SAEs were collected from start of the study treatment up to Day 27 Safety Population consisted of all participants who received at least 1 dose of study medication.	6.2% 1/16 • Non-SAEs and SAEs were collected from start of the study treatment up to Day 27 Safety Population consisted of all participants who received at least 1 dose of study medication.
Ear and labyrinth disorders Ear pruritus	0.00% 0/16 • Non-SAEs and SAEs were collected from start of the study treatment up to Day 27 Safety Population consisted of all participants who received at least 1 dose of study medication.	0.00% 0/16 • Non-SAEs and SAEs were collected from start of the study treatment up to Day 27 Safety Population consisted of all participants who received at least 1 dose of study medication.	6.2% 1/16 • Non-SAEs and SAEs were collected from start of the study treatment up to Day 27 Safety Population consisted of all participants who received at least 1 dose of study medication.
Injury, poisoning and procedural complications Skin abrasion	6.2% 1/16 • Non-SAEs and SAEs were collected from start of the study treatment up to Day 27 Safety Population consisted of all participants who received at least 1 dose of study medication.	0.00% 0/16 • Non-SAEs and SAEs were collected from start of the study treatment up to Day 27 Safety Population consisted of all participants who received at least 1 dose of study medication.	0.00% 0/16 • Non-SAEs and SAEs were collected from start of the study treatment up to Day 27 Safety Population consisted of all participants who received at least 1 dose of study medication.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/16 • Non-SAEs and SAEs were collected from start of the study treatment up to Day 27 Safety Population consisted of all participants who received at least 1 dose of study medication.	6.2% 1/16 • Non-SAEs and SAEs were collected from start of the study treatment up to Day 27 Safety Population consisted of all participants who received at least 1 dose of study medication.	0.00% 0/16 • Non-SAEs and SAEs were collected from start of the study treatment up to Day 27 Safety Population consisted of all participants who received at least 1 dose of study medication.
Psychiatric disorders Anxiety	0.00% 0/16 • Non-SAEs and SAEs were collected from start of the study treatment up to Day 27 Safety Population consisted of all participants who received at least 1 dose of study medication.	6.2% 1/16 • Non-SAEs and SAEs were collected from start of the study treatment up to Day 27 Safety Population consisted of all participants who received at least 1 dose of study medication.	0.00% 0/16 • Non-SAEs and SAEs were collected from start of the study treatment up to Day 27 Safety Population consisted of all participants who received at least 1 dose of study medication.

Additional Information

GSK Response Center

ViiV Healthcare

Phone: 866-435-7343

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
Publication restrictions are in place

Restriction type: OTHER